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INTRODUCTION
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Rheumatic Heart disease has been one of the major health problems in developing 
countries like India. This is an autoimmune disease which occurs in the cardiac tissues 
due to streptococcal throat infection. Pancarditis and particularly vasculitis contributes 
the major complication following this disease. Mitral valve constitutes about 50 % of 
the valve which gets affected due to rheumatic heart disease. Pulmonary Hypertension 
is said to complicate about 70% of the patients affected by this disease. Pulmonary 
Hypertension adversely affects the prognosis and course of the disease. 
Pulmonary Hypertension in mitral valvular heart disease leads to various adverse 
outcome following surgical treatment of this condition. In majority of the patients this 
Pulmonary Hypertension is reversible following surgery. In considerable number of 
patients however the persistence of Pulmonary Hypertension leads to postoperative 
problems which may result in death. 
 
Understanding the Pathophysiology of the Pulmonary  Hypertension occurring due to 
this disease and analyzing it before embarking on the treatment option would largely 
benefit the team involved in the care of suffering patients. 
Management of Pulmonary Hypertension before surgery involves investigations and 
manipulation with certain drugs which may reduce the Pulmonary pressures before 
proceeding towards surgical correction. 
 
An attempt of a prospective study to analyze the facts is made and the results are 
tabulated and compared to the national and international views on the same parameter 
of this common disease.  
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Pulmonary Hypertension is diagnosed clinically by identifying loud P2 component of 
2nd Heart sound, TR Murmur and the accompanying ECG changes  
 
like Right Atrial enlargement, Right Axis deviation and electrical rotation of the 
Heart.  
Pulmonary Hypertension is readily identified by Echocardiography which is also used 
to classify the pressures into mild, moderate and severe categories. Catheterization 
studies are not done routinely as echocardiogram has emerged as an effective tool to 
identify Pulmonary Hypertension and classify accordingly. 
In our study which was conducted for a period of 2 years from July 2007 to July 2009 
we had recorded data of about 265 patients with Mitral Stenosis or Mitral 
Regurgitation cases with severe Pulmonary Hypertension. We had investigated them 
with preoperative ECHO and introperative PAP measurement using transducers and 
followed them with postoperative Echocardiogram for about 6 months. 
All patients were well informed about the procedure and appropriate consent had been 
obtained prior to the valve replacement. 
The results obtained from the data collection were tabulated and analyzed using 
various parameters which may affect the outcome of the patients and were statistically 
scrutinized using appropriate software. 
 
  8
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REVIEW OF LITERATURE 
 
PULMONARY  HYPERTENSION -MECHANISM 
Patients with Rheumatic Heart Disease develop Pulmonary Hypertension due to 
various reasons and prime cause among them will be the retrograde transmission of 
LA Hypertension which gets transmitted to the Pulmonary arteries. Pulmonary venous 
pressure also is transmitted to Pulmonary arteries. There is also reactive Pulmonary 
Arteriolar constriction which can lead to Pulmonary Hypertension. For some unknown 
reasons there are morphological changes in Pulmonary Vasculature which can lead to 
the development of Pulmonary Hypertension. Interstitial Oedema which can occur due 
to elevated LA pressure >20 mmHg can also lead to the development of Pulmonary 
Hypertension.  
Pathophysiology of Pulmonary Hypertension 
   Elevated LA pressure 
   Elevated Pulmonary venous pressure 
   Transmitted pulmonary venous hypertension to arteries 
   Vasoconstriction of Pulmonary arterioles 
   Pulmonary Artery Hypertension 
   Right ventricular dilatation  
   Tricuspid Regurgitation  
    Right Atrial enlargement 
    Congestive cardiac failure  
 
The above flow chart explains the Pathophysiology of Pulmonary Hypertension in 
Mitral Valvular heart disease in both Rheumatic Mitral Stenosis and Regurgitation. 
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Pulmonary Hypertension greatly influences the natural course of the disease process, 
treatment response and also the post intervention prognosis. 
Wood et al had noted that severe PHT was associated with both moderate MS and 
severe MS. Fawzy and Reibero pointed out that there is another group of patients with 
severe MS, yet only a mild increase in PAP. The reasons for not developing PHT in 
these cases are not clear. No significant relation between LA size and PAP has been 
noted. There is a view that the increase in LA size would cushion of the sequelae of 
increase in pressure. 
 
Bahl et al and Krishnamoorthy et al had observed that PHT is an indicator of disease 
severity in patients with Mitral Stenosis. Chronicity of the disease process as indicated 
by the presence of severe fibrosis and Atrial Fibrillation are important in the 
development of reactive PHT  
 
FEATURES INDICATING SEVERITY OF DISEASE IN MITRAL 
VALVULAR LESIONS COMPLICATED BY PULMONARY 
HYPERTENSION 
¾ Severe Subvalvular Pathology 
¾ Small Mitral Valve Area 
¾ Higher Transvalvular gradient 
¾ Higher Pulmonary  valve resistance 
¾ Higher NYHA symptoms 
¾ Thickened non pliable valves 
¾ Higher Wilkins score 
¾ Higher incidence of Atrial Fibrillation. 
  11
DEFINITION: 
In medicine, Pulmonary  Hypertension (PH or PHT) is an increase in blood pressure 
in the Pulmonary  artery, Pulmonary  vein, or Pulmonary  capillaries, together known 
as the Lung Vasculature, leading to shortness of breath, dizziness, fainting, and other 
symptoms, all of which are exacerbated by exertion. Pulmonary Hypertension can be a 
severe disease with a markedly decreased exercise tolerance and heart failure. It was 
first identified by Dr. Ernst von Romberg in 1891 
The Venice 2003 revised classification system can be summarized as follows. 
WHO Group I - Pulmonary Arterial hypertension (PAH)  
Idiopathic (IPAH)  
Familial (FPAH)  
Associated with other diseases (APAH): Collagen Vascular Disease (e.g. 
Scleroderma), congenital shunts between the systemic and Pulmonary Circulation, 
portal hypertension, HIV infection, drugs, toxins, or other diseases or disorders  
Associated with venous or capillary disease  
WHO Group II - Pulmonary Hypertension associated with left heart disease  
Atrial or Ventricular disease  
Valvular disease (e.g. Mitral Stenosis)  
WHO Group III - Pulmonary Hypertension associated with lung diseases and/or 
Hypoxemia  
Chronic Obstructive Pulmonary disease (COPD), Interstitial Lung Disease (ILD)  
Sleep-disordered breathing, Alveolar Hypoventilation  
Chronic exposure to high altitude  
Developmental lung abnormalities  
WHO Group IV - Pulmonary Hypertension due to chronic thrombotic and/or embolic 
disease  
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Pulmonary Embolism in the proximal or Distal Pulmonary Arteries  
Embolization of other matter, such as tumor cells or parasites  
WHO Group V - Miscellaneous  
This Classification does not include sickle cell disease, Human Herpesvirus 8, also 
associated with Kaposi's sarcoma, and has been demonstrated in patients with PAH, 
suggesting that this virus may play a role in its development. Recent studies have been 
unable to find an association between human Herpesvirus 8 and Idiopathic Pulmonary 
Arterial Hypertension. 
 
Pulmonary Hypertension – Heath Edwards grading system 
Grade Microscopic Features 
Potentially Reversible 
I 
Hypertrophy of the media of muscular Pulmonary Arteries. Extension of 
muscle into the wall of Pulmonary Arterioles. 
II 
Muscle Hypertrophy plus proliferation of intimal cells in arterioles and 
small muscular arteries. 
III 
"Muscle hypertrophy plus sub endothelial fibrosis. Eventually, concentric 
masses of fibrous tissue and reduplicated internal elastic lamina occlude the 
vascular lumen of arterioles and small muscular arteries. Large elastic 
arteries show atherosclerosis." 
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Grade Microscopic Features 
Usually Irreversible 
IV 
"Muscle hypertrophy is less apparent; progressive dilatation of small 
arteries, especially those near vessels with Intimal fibrous occlusion. 
Plexiform lesions occur." 
V 
Plexiform and Angiomatoid lesions plus intra-alveolar Hemosiderin-filled 
macrophages. 
VI 
Necrotizing Arteritis with thrombosis. Fibrinoid necrosis of the arterial wall 
with a Transmural infiltrate of Polymorphonuclear leukocytes and 
Eosinophils. 
Usually Pulmonary Hypertension grade 3 and below are reversible and can be taken 
up for surgery with better results. Pulmonary Hypertension grade 4 and above has 
significant contribution for postoperative morbidity and mortality. 
 
PATHOLOGICAL FINDINGS: 
Pathological changes in lungs in rheumatic MS include prominent vascular and 
parenchymal changes. Pulmonary veins develop muscular media. Moderate to marked 
medial hypertrophy occurs in medium sized branches of the Pulmonary arteries. 
Dilatation lesions and plexiform lesions are rarely seen in rheumatic MS .Tandon et al 
and Chopra et al has reported such lesion in 4% of the autopsy studies conducted in 
New Delhi, India. Mubeen et al, recently has reported that Pulmonary vascular 
changes do not go beyond grade 3 (Heath Edward) criteria in RHD. The most striking 
feature seen is prominent smooth muscle layer in Bronchoalveolar walls. The extent 
and severity of both vascular and parenchymal changes are seen more in juvenile MS. 
Haemosiderosis has been reported in long standing cases. 
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TREATMENT OPTIONS: 
¾ MEDICAL  
¾ INTERVENTIONAL 
¾ SURGICAL  
 
MEDICAL: 
Patients with Mitral Valvular heart disease and PHT are started with rate controlling 
drugs and diuretics once they become symptomatic. Rate controlling drugs like Beta-
blocker and Calcium channel blockers are started to control AF which otherwise 
would worsen the condition. Rate control with these drugs help in reducing the 
Transmitral gradient and hence the PHT. Digoxin is usually started for the failing 
heart and RV dysfunction which has to pump blood against severe Pulmonary 
Hypertension.  
 
INTERVENTIONAL: 
Isolated MS and PHT were treated by closed Mitral Commisurotmy (CMC) and 
Balloon Mitral Valvotomy (BMV) from time immemorial. Balloon Mitral Valvotomy 
can be attempted only if the valves are pliable and the Wilkins score is favorable. 
There are many concerns before proceeding to BMV like the less tolerance to the 
stress of the procedure, difficulty in negotiating the septum in large right sided 
chambers, Tight Mitral Stenosis and fear of tearing the mitral valve and creating 
Mitral Regurgitation. However the AHA GUIDELINES 2008 clearly states the role of 
BMV in a case of severe PHT associated with rheumatic heart disease. Even though 
BMV has given good results in MS and PHT the mitral valve area remained less on 
comparison with open procedures with reasonable reduction in Pulmonary vascular 
resistance and PAP. 
 
  15
 
SURGICAL: 
Patient’s hemodynamic performance was better following reduction in Pulmonary 
vascular resistance particularly after MVR and valvotomy. Pulmonary Hypertension 
regresses after the transmitral gradient reduced following surgery. Hemodynamic 
studies done in patients who had undergone MVR showed a reversibility of 
Pulmonary Artery Hypertension19. Various options are open for surgical management 
of this condition like Mitral valve replacement (MVR), Closed Mitral Commisurotmy 
and Open Mitral Valvotomy. Mitral Valve Replacement may be done with either 
mechanical prosthetic valve or Bioprosthetic Valve Autologous transfer of Pulmonary 
valve (ROSS II PROCEDURE) has also been done for this condition. 
Cesjnvar8 et al has reported higher early mortality among his series of 382 patients 
who underwent MVR for Mitral Valvular disease with Pulmonary Hypertension. But 
the late mortality was no different among patients with or without Pulmonary 
Hypertension. Aris9 et al has confirmed this finding with his series of 88 patients. 
Perioperative mortality with patients having Suprasystemic Pulmonary Arterial 
pressures were 5 times more than with normal or sub systemic pressures. 
In view of this fact subjecting patients with Mitral Valvular heart disease for earlier 
surgical intervention would ameliorate the condition before developing severe 
Pulmonary Hypertension. 
 
PERSISTENT PHT FOLLOWING MVR  
Following MVR majority of the patients have regression of PAP, yet Pulmonary 
Vascular hypertension remains unchanged in significant proportion of patients19. 
Patients with Suprasystemic PAP continue to have persistently elevated PVR. Patients 
with irreversible PHT after MVR are found to have early mortality. Compared to 
patients who have AF, regaining sinus rhythm after MVR results in reduction in PAP. 
Patient –prosthetic mismatch contributes significantly to the persistence of Pulmonary 
Hypertension after MVR. Recent studies had demonstrated the correlation between   
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persistent PHT and patient –prosthesis mismatch and associated poor prognosis. 
Patient –prosthesis mismatch occurs with both mechanical and Bioprosthesis Valves. 
 
TRICUSPID REGURGITATION AND PHT  
Functional TR occurs following severe PHT in a Rheumatic Mitral Valvular heart 
disease. There are conflicting reports regarding the resolution of TR following Mitral 
Valve Replacement. Persistence of TR may contribute to the mortality and morbidity 
following surgeries done for mitral valve disease. Some times simultaneous TR repair 
is recommended during surgeries done for mitral valve disease. Patients with severe 
PHT show regression of TR following MVR and other surgeries for mitral valve 
disease.  
 
PERIOPERATIVE MANAGEMENT OF PHT PATIENTS 
Perioperative mortality is higher with patients having severe PHT and mitral valvular 
heart disease. But late survival curves are similar for patients with or without 
Pulmonary Hypertension, therefore effective perioperative management of severe 
Pulmonary Hypertension would help in the late survival of these patients and there 
would be no significant difference in the Kaplan-Meier survival curves. 
Various drugs are available for managing these patients perioperatively like milrinone, 
nesiridite, inhaled nitric oxide and prostacyclin and on the horizon we also have 
sildanefil and endothelin antagonist like bosentan etc which  has  been  used  both 
preoperatively  and  postoperatively . 
Role  of  phenoxybenzamine  has  been  found  be  useful  in  cases  of  Pulmonary  
Hypertension  secondary  to  congenital  heart  disease  and  in  the  peri  and 
postoperative  periods  of  congenital  heart  disease  correction  especially  with 
elevated  Pulmonary   vascular  resistance . 
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TREATMENT TARGETED AT PULMONARY VASCULATURE 
 
So far traditionally treatment for mitral valvular heart disease focused only on cardiac 
physiology. Now the recent concepts are focusing more in the Pulmonary Vascular 
physiology following mitral valve disease and are due to the renewed interest in 
Cardio Pulmonary Hemodynamics.  Madden15 et al has recently found the role of 
phosphodiesterase 5 inhibitor (sildenafil) in a study conducted by him and found to 
have a positive role in treating these patients. The therapy has been found to be 
significantly tolerated and results are good as early as 8 weeks .Even exercise 
tolerance seems to be improved with this   medicine. 
 
PULMONARY VASCULAR RESISTANCE 
Pulmonary vascular resistance has two components an organic element and dynamic 
element. Dynamic component is relieved immediately following reduction of LA 
pressures. Organic element due to changes in Pulmonary vascular changes regresses 
immediately or may take a long time to do. Kaul and colleagues reported on 30 
patients with severe Pulmonary Hypertension which showed striking regression from 
a mean of 74mm Hg. Restudy an average of 5.5 years after MVR showed an average 
systolic pressure of 48mmHg and mean of 31 mmHg. This drop was largely due to 
sudden reduction of LA pressure and reversal of severe spastic Pulmonary 
vasoconstriction that accompanies left Atrial Hypertension. These changes in 
Pulmonary vascular resistance are a progressive regression and are the same for both 
stenosis and regurgitation. In older patients and in patients with AF the regression 
occurs less frequently. 
 
CALCULATION OF PULMONARY  ARTERY PRESSURE 
Using  Doppler  we  can  measure  the  Pulmonary   artery  pressure  using  the peak  
Transtricuspid  flow  velocity   (VMAX). 
PAP   = 4V max2 + RIGHT ATRIAL PRESSURE. 
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RAP  is  usually  equal  to  jugular  venous  pressure  measured  clinically  or  from  
the  Inferior  Vena  Cava  diameter  measured  in  Expiration   and  percentage  
collapse  of  IVC  in   Inspiration   . 
 
MITRAL STENOSIS 
The mitral valve is made up of the annulus, anterior and posterior leaflets, and 
chordae, which attach the leaflets to their respective papillary muscles. A normally 
functioning valve allows blood to flow unimpeded from the left atrium to the left 
ventricle during diastole and prevents regurgitation during systole. Normal mitral 
valve function is dependent not only on the integrity of the underlying valvular 
structure, but on that of the adjacent myocardium as well. 
 
Definition and Causes 
Mitral stenosis (MS) refers to narrowing of the mitral valve orifice, resulting in 
impedance of filling of the left ventricle in diastole. It is usually caused by rheumatic 
heart disease. Less common causes include severe calcification of the mitral annulus, 
infective endocarditis, systemic lupus erythematosus, rheumatoid arthritis, and 
carcinoid heart disease. 
 
Pathophysiology and Natural History 
Patients with MS typically present more than 20 years after an episode of rheumatic 
fever. Single or recurrent bouts of Rheumatic Carditis cause progressive thickening, 
scarring, and calcification of the mitral leaflets and chordae. Fusion of the 
commissures and chordae decreases the size of the mitral opening. This obstruction 
results in the development of a pressure gradient across the valve in diastole and 
causes an elevation in left atrial and Pulmonary venous pressures. Elevated left atrial 
pressures lead to left atrial enlargement, predisposing the patient to Atrial Fibrillation 
and Arterial Thromboembolism. Elevated Pulmonary Venous pressure results in 
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Pulmonary Congestion and Pulmonary Edema. In advanced mitral stenosis, patients 
develop Pulmonary Hypertension and right-sided heart failure. 
 
Signs and Symptoms 
Patients with mitral stenosis may present with Exertional Dyspnea, fatigue, atrial 
arrhythmias, embolic events, angina-like chest pain, Hemoptysis, or even right-sided 
heart failure. Previously asymptomatic or stable patients may decompensate acutely 
during exercise, emotional stress, pregnancy, infection, or with uncontrolled atrial 
fibrillation. 
The characteristic findings of MS on auscultation are an accentuated first heart sound, 
an opening snap, and a mid-diastolic rumble. The first heart sound may be diminished 
in intensity if the valve is heavily calcified, with limited mobility. If the patient is in 
sinus rhythm, there is presystolic accentuation of the murmur during atrial contraction. 
With increasingly severe stenosis, the duration of the murmur increases and the 
opening snap occurs earlier during diastole as a result of higher left atrial pressure. 
There is accentuation of P2 when Pulmonary Hypertension is present. If flow across 
the mitral valve is reduced because of heart failure, Pulmonary Hypertension, or aortic 
stenosis the murmur of mitral stenosis may be reduced in intensity or may be 
inaudible. 
Left Atrial Myxoma may be distinguished from MS by the presence of a “tumor plop” 
versus an opening snap in early diastole. 
 
Diagnosis 
On chest radiography, the characteristic findings of mitral stenosis are pulmonary 
congestion, enlargement of the main Pulmonary arteries, and enlargement of the left 
atrium without cardiomegaly. An electrocardiogram (ECG) may reveal evidence of 
left atrial enlargement, Atrial Fibrillation or, in advanced disease, right ventricular 
hypertrophy consistent with Pulmonary Hypertension. 
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Two-dimensional (2D) and Doppler echocardiography is indicated for all patients with 
suspected MS to confirm the diagnosis and determine its severity (Class I indication). 
Characteristic findings of MS include valve thickening, restricted valve opening, 
anterior leaflet doming, and fusion of the leaflets at the commissures. The mean 
pressure gradient across the mitral valve on Doppler echocardiography (echo) in MS 
is at least 5 mm Hg; in severe stenosis, it is usually higher than 10 mm Hg. Because 
the gradient across the mitral valve is flow dependent, the severity of MS is more 
accurately defined by the mitral valve area (MVA). The normal valve area is 4 to 5 
cm2. In mild mitral stenosis, the MVA is 1.5 to 2 cm2, in moderate stenosis it is 1 to 
1.5 cm2, and in severe stenosis it is less than 1 cm2. The valve area may be measured 
by tracing the mitral valve opening in cross section by 2D echo. Alternatively, the 
MVA is calculated using the pressure half-time (P ×-½t), which is the amount of time 
it takes for the transmitral pressure to fall to one half its initial value (MVA = 220/[P 
×- ½t]).  
 
Echocardiography also allows assessment of Pulmonary artery pressures, detection of 
other valve disease, visualization of left atrial thrombus, and identification of 
important differential diagnoses, such as Left Atrial Myxoma. Tran esophageal echo is 
superior to transthoracic echo at identifying left atrial thrombus in patients who are 
being considered for Percutaneous Mitral Balloon Valvotomy or Cardio Version. 
Stress echocardiography may be helpful if there is a discrepancy between a patient's 
severity of symptoms and the baseline hemodynamic data. An exercise mean 
transmitral gradient of more than 15 mm Hg and peak right ventricular systolic 
pressure of more than 60 mm Hg indicate hemodynamically significant MS. 
Cardiac catheterization is not necessary in all cases but, like stress echocardiography, 
may be helpful in characterizing the severity of mitral stenosis when there is a 
discrepancy between symptoms and findings on echocardiography. 
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Treatment 
Medical Treatment  
Medical therapy has no role in altering the natural history or delaying the need for 
surgery in patients with MS. Medical treatment is directed toward alleviating 
Pulmonary Congestion with diuretics, treating Atrial Fibrillation, and anticoagulating 
patients who are at increased risk of arterial embolic events. 
Development of Atrial Fibrillation frequently leads to an acute deterioration in 
patients with mitral stenosis. The rapid ventricular response results in a decrease in the 
diastolic filling time. Beta blockers, calcium channel blockers, or digoxin may be used 
to control ventricular rate. An attempt to restore sinus rhythm with direct current 
electrical cardioversion or antiarrhythmic drugs may be considered. Anticoagulation 
with warfarin is indicated to prevent thromboembolism when Atrial Fibrillation is 
present, if there is a prior history of thromboembolism, or a thrombus is detected in 
the left atrium (Class I). Although controversial, anticoagulation may also be 
considered if the left atrium is markedly dilated (5.0 to 5.5 mm) or if there is 
spontaneous contrast on echocardiography (Class II b).  
Antibiotic therapy is important for the secondary prevention of Rheumatic Carditis. 
Patients with a history of rheumatic fever are at high risk of recurrence. Long-term 
secondary prophylaxis, preferentially with penicillin, is therefore recommended for all 
patients with a history of rheumatic fever or suspected rheumatic valve disease. The 
duration of prophylaxis depends on a number of factors, including the time lapsed 
since the last attack, the age of the patient, the presence or absence of cardiac 
involvement, and the patient's risk of exposure to streptococcal infections. Routine 
antibiotic prophylaxis for endocarditis is no longer recommended for patients with 
mitral stenosis.  
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Surgery  
Three invasive options are available for patients with MS: (1) Percutaneous Mitral 
Balloon Valvotomy (PMBV); (2) Surgical Mitral Commissurotomy; and (3) Mitral 
Valve Replacement (MVR). In experienced centers, PMBV is the initial procedure of 
choice and should be considered for (1) symptomatic patients (NYHA functional 
Classes II to IV) with moderate or severe MS (Class I) and (2) asymptomatic patients 
with moderate or severe MS and Pulmonary Hypertension (Class I). PMBV is a 
catheter-based technique in which a balloon is inflated across the stenotic valve to 
split the fused commissures and increase the valve area. The MVA typically doubles 
in size, and hemodynamic as well as clinical improvements are seen immediately. The 
results are comparable with those achieved with open Mitral Commissurotomy, but it 
is less invasive and less costly. The Mitral Valve Morphology is an important 
predictor of successful balloon valvotomy. Severe valve calcification or significant 
involvement of the subvalvular apparatus on echocardiography before PMBV is 
associated with a higher complication rate and a greater risk of recurrence. In addition, 
balloon valvotomy should not be performed in patients who have left atrial thrombus 
or more than 2+ (moderate) mitral regurgitation, because the degree of mitral 
regurgitation usually increases following the procedure. Complications of Balloon 
Mitral Valvotomy include severe Mitral Regurgitation (3%), Thromboembolism (3%), 
and residual Atrial Septal Defect with significant shunting (less than 5%). Mortality 
with the procedure is lower than 1% in experienced hands. At 7 years after balloon 
valvotomy, 50% to 69% of patients remain free of cardiovascular events and up to 
90% of patients remain free of reintervention.  However, both Balloon Valvotomy and 
Surgical Commissurotomy are palliative procedures and, in most cases, further 
intervention is eventually required, usually in the form of a Mitral Valve Replacement. 
In patients with calcified valves that cannot be treated by valvotomy or 
commissurotomy, or in those with significant mitral regurgitation that is not suitable 
for repair, mitral valve replacement may be necessary. The threshold for Mitral Valve 
Surgery (commisurotmy or MVR) is higher than for PMBV in patients with Mitral 
Stenosis, and commisurotmy or repair is preferable to MVR, if feasible. Surgery for 
  23
moderate to severe Mitral Stenosis is indicated for symptomatic patients (New York 
heart association [NYHA] functional class iii or iv) where PMBV  is unavailable or 
contraindicated (class i). MVR may also be considered for patients with severe MS 
and severe Pulmonary Hypertension with NYHA functional classes i or ii symptoms 
who are not candidates for PMBV or Mitral Valve Repair (class iia). Both mechanical 
and biologic prostheses are used for MVR; the choice of valve often depends on 
factors such as age, need for Concomitant Anticoagulation, and Left Ventricular (LV) 
size. Morbidity and mortality are higher with prosthetic valve replacement than with 
surgical or balloon valvotomy.  
 
Definition and Causes 
Mitral Regurgitation (MR) is leakage of blood from the left ventricle into the left 
atrium during systole. It is caused by various mechanisms related to structural or 
functional abnormalities of the mitral apparatus, adjacent myocardium, or both. The 
most common causes of mitral regurgitation are rheumatic heart disease, myxomatous 
degeneration, chordal rupture, infective endocarditis, coronary artery disease, and 
cardiomyopathy . 
 
Pathophysiology and Natural History 
Significant MR leads to volume overload of the left ventricle, because it has to 
accommodate both the stroke volume and regurgitant volume with each heartbeat. To 
compensate, the left ventricle dilates and becomes hyperdynamic. In acute severe MR, 
the left atrial and pulmonary venous pressures increase quickly, leading to pulmonary 
congestion and Pulmonary Edema. In chronic MR, a gradual increase in left atrial size 
and compliance compensate so that left atrial and pulmonary venous pressures do not 
increase until late in the course of the disease. Progressive left ventricular dilation 
eventually leads to an increase in afterload, contractile dysfunction, and heart failure. 
Left atrial enlargement predisposes the patient to Atrial Fibrillation and Arterial 
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Thromboembolism. In long-standing MR, patients may develop Pulmonary  
Hypertension and right-sided heart failure. 
 
Signs and Symptoms 
Patients with chronic, severe mitral regurgitation may remain asymptomatic for years 
because the regurgitant volume load is well tolerated as a result of compensatory 
ventricular and atrial dilation. When symptoms do develop, the most common are 
dyspnea, fatigue, orthopnea, paroxysmal nocturnal dyspnea, and palpitations caused 
by Atrial Fibrillation. Acute severe MR, as occurs with chordal rupture or papillary 
muscle rupture, is almost always symptomatic because the sudden regurgitant volume 
load in the nondilated left ventricle and atrium leads to Pulmonary venous 
hypertension and congestion. 
 
The characteristic finding in a patient with MR is a blowing holosystolic murmur 
heard best at the cardiac apex. When ventricular enlargement is present, the apical 
impulse may be diffuse and laterally displaced, and a third heart sound may be heard. 
 
Diagnosis 
The chest radiograph demonstrates left atrial enlargement and cardiomegaly. Two-
dimensional and Doppler echocardiography is indicated for all patients with suspected 
mitral regurgitation to confirm its presence and determine its severity (Class I). Two-
dimensional echocardiography usually reveals the cause (e.g., the presence of 
myxomatous mitral valve disease and leaflet prolapse or evidence of underlying 
dilated cardiomyopathy). Evaluation of the severity of Mitral Regurgitation on 
echocardiography requires an integrated assessment of several parameters, including 
regurgitant jet size by Color Doppler, Regurgitant Jet Density by continuous-wave 
(CW) Doppler, and Pulmonary vein and Mitral Valve inflow by pulse-wave (PW) 
Doppler. Newer applications of Doppler echocardiography allow quantitative 
measurement of mitral regurgitation, including the regurgitant volume and the 
  25
regurgitant orifice area (ROA)—that is, the area through which the valve leaks in 
systole. In asymptomatic patients with significant mitral regurgitation, serial 
echocardiography every 6 to 12 months to assess LV size and systolic function is 
important for optimal timing of surgery (Class I). Transesophageal echocardiography 
is indicated for patients who are not adequately imaged by transthoracic 
echocardiography and before surgery to assess feasibility for repair (Class I). Stress 
echocardiography may be useful to assess exercise tolerance and the response of 
mitral regurgitation severity, Pulmonary pressure, and contractile reserve to exercise 
in asymptomatic patients with significant MR (Class IIa).  
 
Cardiac catheterization is no longer routinely performed to evaluate mitral 
regurgitation severity, but it is indicated for those patients in whom noninvasive test 
results are inconclusive, and also to detect concomitant Coronary Artery Disease 
(CAD) in patients undergoing mitral valve surgery (Class I).  
 
Treatment 
Medical Treatment  
In patients with acute severe MR, afterload reduction with intravenous nitroprusside 
and nitroglycerin reduces the regurgitant fraction and Pulmonary pressures. Placement 
of an intra-aortic balloon pump also helps stabilize these patients. However, these are 
temporary measures before urgent mitral valve repair or replacement. In patients with 
chronic asymptomatic Mitral Regurgitation caused by primary valve disease, there is 
no evidence for the routine use of medication in delaying the need for surgery or 
preventing left ventricular dysfunction. The management of these patients is focused 
on deciding on the appropriate timing of surgery, before the development of 
irreversible left Ventricular Dysfunction. Patients should be followed up every 6 to 12 
months to assess for symptoms and to measure left ventricular size, function, and 
severity of MR by echocardiography (Class I).  
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In patients with ischemic heart disease or dilated cardiomyopathy, mitral regurgitation 
indicates a poor prognosis. MR in these patients is called functional mitral 
regurgitation and is caused by global or regional changes in left ventricular geometry 
as well as annular dilation. Functional MR is primarily treated medically with 
antihypertensive therapy, Angiotensin Converting Enzyme (ACE) inhibitors, beta 
blockers, diuretics, and antianginal therapies when mitral regurgitation is worsened by 
acute ischemia. Biventricular Pacing has also been shown to decrease the degree of 
mitral regurgitation in dilated cardiomyopathy.  
Routine antibiotic prophylaxis for endocarditis is no longer recommended for patients 
with mitral regurgitation.  
 
Surgery  
Surgery is indicated for (1) symptomatic patients with severe primary MR (Class I) 
and (2) asymptomatic patients with severe primary MR and evidence of LV 
dysfunction (Class I). Optimal timing of mitral valve surgery is challenging in 
asymptomatic patients because the actual contractile function of the left ventricle is 
difficult to measure. The standard indications for surgery in asymptomatic patients are 
an LV end-systolic dimension of more than 4.0 cm and a resting LV ejection fraction 
of less than 60% (Class I). Other indications in asymptomatic patients include 
Pulmonary Hypertension or development of Atrial Fibrillation (Class IIa). In addition, 
mitral valve repair may be undertaken in experienced surgical centers for 
asymptomatic patients with severe MR, but without evidence of LV dilation or 
dysfunction, for which the likelihood of a successful repair is greater than 90% (Class 
IIa). Most asymptomatic patients with severe MR develop symptoms, LV dysfunction, 
or both over long-term follow-up. One retrospective study showed an increased risk of 
cardiac death (4%/year) in patients with severe mitral regurgitation based on an ROA 
of more than 0.4 cm2. However, another recent prospective study has shown that 
careful follow-up of patients with severe MR and timing of surgery based on 
symptoms, LV dysfunction, development of Atrial Fibrillation, or Pulmonary  
Hypertension is associated with an excellent patient outcome.  
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In patients with severe functional mitral regurgitation, surgery may be considered for 
severe symptoms despite medical therapy. Patients with ischemic MR may improve 
with coronary bypass surgery if significant ischemia or myocardial viability is present. 
In many coronary bypass patients with MR, concomitant mitral valve repair with an 
undersized annuloplasty ring is performed. Patients with severe left ventricular 
dysfunction and significant MR were once believed to be poor surgical candidates, but 
recent studies have shown an acceptable operative risk. Symptoms usually improve, 
although a survival benefit has not been demonstrated. 
 
The two available surgical options are mitral valve repair and mitral valve 
replacement. Mitral valve repair is the procedure of choice in the surgical 
management of MR caused by degenerative valve disease and in some cases of MR 
caused by infective endocarditis and ischemic heart disease. Repair offers several 
advantages over replacement, including lower operative time and long-term mortality, 
better preservation of LV function, a lower risk of subsequent infective endocarditis, 
and no need for long-term anticoagulation. Reoperation rates for mitral valve repair 
and replacement are similar, occurring at a rate of 1% to 2% per year. On the other 
hand, repair is technically more difficult than replacement, and many cases of mitral 
regurgitation are not amenable to valve repair. Percutaneous mitral valve repair is 
currently being investigated. The techniques involved include a clip that joins the 
mitral leaflets at their midpoint and an annuloplasty ring delivered via the coronary 
sinus.. 
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AIMS AND OBJECTIVES 
 
• A Prospective study to analyze preoperative and postoperative Pulmonary 
Hypertension following mitral valvular heart disease using preoperative 
echocardiogram, intraoperative pressure studies and postoperative 
echocardiogram. 
 
• To analyze the reduction in Pulmonary Hypertension following mitral valve 
replacement during patient follow up post surgically. 
 
• To study the effect of pharmacological agents in reduction of Pulmonary 
Hypertension preoperatively and postoperatively in mitral valvular heart 
disease. 
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MATERIALS AND METHODS 
A total of 265 patients were taken in this prospective study who came to the hospital 
with NYHA Class II-IV symptoms and with Mitral valvular heart lesions comprising 
of Mitral stenosis and Mitral Regurgitation with Pulmonary Hypertension from period 
of July 2007 –July 2009. 
 
A detailed clinical examination and investigations were done on these patients and 
were categorized according to the study. All patients were prepared and consented 
before surgery as per the protocol and were operated under same conditions. All of 
them underwent Mitral valve replacement using St Jude’s medical valve using 
cardiopulmonary   bypass support. 
 
A detailed clinical findings and preoperative values of these 265 patients are recorded 
over a structured proforma (Annexure) for all the patients. 
 
All the patients are classified according to their age, sex, diagnosis, preoperative, 
intraoperative and post operative echo findings and result after surgery. The results 
thus obtained are tabulated and statistically analyzed and conclusions drawn 
thereafter. 
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OBSERVATIONS AND RESULTS 
265 Patients with mitral valvular heart disease and Pulmonary Hypertension who were 
admitted in government general hospital during July 2007-july 2010 were classified 
into different groups and tabulated according to different variables as follows: 
 
AGE GROUP Vs PULMONARY  HT SEVERITY PRE OPERATIVE 
  
 
 
Severity Levels 
1- Severe 2-Non-Severe  
1 2 Total 
AGE GROUP 
 
 
 
 
 
 
 
 
 
 
 
1 
 
(10-
19)    
Count 26 10 36 
% within PULMONARY 
HT SEVERITY PRE OP 
13.3% 14.3% 13.6% 
% of Total 9.8% 3.8% 13.6% 
2 
 
(20-
29) 
Count 48 16 64 
% within PULMONARY 
HT SEVERITY PRE OP 
24.6% 22.9% 24.2% 
% of Total 18.1% 6.0% 24.2% 
3 
(30-
39) 
Count 61 18 79 
% within PULMONARY 
HT SEVERITY PRE OP 
31.3% 25.7% 29.8% 
% of Total 23.0% 6.8% 29.8% 
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Cont.. 
 
 
Severity Levels 
1- Severe 2-Non-Severe  
1 2 Total 
 4 
 
(40-
49) 
Count 50 22 72 
% within PULMONARY 
HT SEVERITY PRE OP 
25.6% 31.4% 27.2% 
% of Total 18.9% 8.3% 27.2% 
5 
 
(>50) 
Count 10 4 14 
% within PULMONARY 
HT SEVERITY PRE OP 
5.1% 5.7% 5.3% 
% of Total 3.8% 1.5% 5.3% 
 Total Count 195 70 265 
% within PULMONARY 
HT SEVERITY PRE OP 
100.0% 100.0% 100.0% 
 
Out of 265 patients analyzed 195 (73.58%) had severe Pulmonary Hypertension and 
remaining 70 patients (26.42 %) had moderate to mild Hypertension. Out of 265 
patients, age group which had affected maximum with PHT was found to be in the 3rd 
to 4th decade which is about 31.3% which is a significant productive group. Next 
group to be affected by this severe PHT was found to be in the 4th to 5th decade (18.9 
%).Age group which had affected the least was found in the 5th decade and beyond.  
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Chi-Square Tests 
 
Value df 
Asymmetrical. Sig. (2-
sided) 
Pearson Chi-Square 1.304a 4 .861 
On performing the chi-square test there was no significant 
correlation between the age group and severe Pulmonary 
Hypertension. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  36
 
 
1)  10-19 Yrs 
2)  20-29 Yrs 
3)  30-39 Yrs 
4)  40-49 Yrs 
5)  >50 Yrs 
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SEX DISTRIBUTION 
 
SEX Vs PULMONARY  HT 
SEVERITY PRE OPERATIVE 
 
 
Severity Levels 
1- Severe 2-Non-Severe 
 1 2 Total 
SEX 1 
(Female )   
Count 111 34 145 
  % within 
PULMONARY  
HT SEVERITY 
PRE OP 
56.9% 48.6% 54.7% 
% of Total 41.9% 12.8% 54.7% 
2 
 
(Male) 
Count 84 36 120 
% within 
PULMONARY  
HT SEVERITY 
PRE OP 
43.1% 51.4% 45.3% 
% of Total 31.7% 13.6% 45.3% 
Total Count 195 70 265 
% within 
PULMONARY  
HT SEVERITY 
PRE OP 
100.0% 100.0% 100.0% 
% of Total 73.6% 26.4% 100.0% 
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According to this study the female patients were affected more with severe Pulmonary 
Hypertension which constitutes about (41.9%)   and male patients constituted about 
31.7% out of the 195 patients who had severe Pulmonary Hypertension. On an 
average about 73.6% of patients had severe Pulmonary Hypertension taking both 
males and females into consideration. The distribution for mild to moderate disease 
was found to be equal. 
Statistical Method 
Value df 
Asymmetric 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 1.450a 1 .229   
 
On performing the chi-square test there was no significant statistical correlation 
between sex and Pulmonary  Hypertension.  
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1) MALE            2) FEMALE 
 
 
 
 
 
 
 
 
 
 
  40
MORTALITY AND PULMONARY HYPERTENSION 
PULMONARY  HT SEVERITY PRE 
OPERATIVE 
Severity Levels 
1- Severe 2-Non-Severe 
1 2 Total 
MORTALITY 0 Count 181 70 251 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
92.8% 100.0% 94.7% 
% of Total 68.3% 26.4% 94.7% 
1 Count 14 0 14 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
7.2% .0% 5.3% 
% of Total 5.3% .0% 5.3% 
 Total Count 195 70 265 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
100.0% 100.0% 100.0% 
% of Total 73.6% 26.4% 100.0% 
 
On analyzing mortality in relation to Pulmonary  Hypertension there were 14 deaths 
(5.3%) out of total number of 265 patients and which includes about 7.2% of 195 
patients known to have severe Pulmonary  Hypertension. About 94.7% patients had 
good postoperative outcome following this surgery done for severe PHT associated 
with Rheumatic Mitral valve disease. 
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Statistical Method 
Value df 
Asymmetric. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 5.306a 1 .021   
On performing the chi-square test there was a significant correlation between severe 
Pulmonary Hypertension and mortality which is a well known factor and this study 
also confirms the hypothesis. 
 
 1- No Mortality 
2-Mortality 
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PATIENTS IN NYHA POST MVR (NYHA Vs PULMONARY  HT SEVERITY 
PRE OPERATIVE) 
PULMONARY  HT SEVERITY PRE 
OPERATIVE 
Severity Levels 
1- Severe 2-Non-Severe 
1 2 Total 
NYHA 1 Count 6 48 54 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
3.3% 68.6% 21.5% 
% of Total 2.4% 19.1% 21.5% 
2 Count 172 22 194 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
95.0% 31.4% 77.3% 
% of Total 68.5% 8.8% 77.3% 
3 Count 3 0 3 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
1.7% .0% 1.2% 
% of Total 1.2% .0% 1.2% 
 Total Count 181 70 251 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
100.0% 100.0% 100.0% 
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PULMONARY  HT SEVERITY PRE 
OPERATIVE 
Severity Levels 
1- Severe 2-Non-Severe 
1 2 Total 
NYHA 1 Count 6 48 54 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
3.3% 68.6% 21.5% 
% of Total 2.4% 19.1% 21.5% 
2 Count 172 22 194 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
95.0% 31.4% 77.3% 
% of Total 68.5% 8.8% 77.3% 
3 Count 3 0 3 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
1.7% .0% 1.2% 
% of Total 1.2% .0% 1.2% 
 Total Count 181 70 251 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
100.0% 100.0% 100.0% 
% of Total 72.1% 27.9% 100.0% 
About 77.3% of patients were in NYHA classification II following this surgery and 
about 21.5% were in NYHA class I followed by 1.2% in NYHA Class III. 
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REDUCTION OF PULMONARY HYPERTENSION 
T-Test 
Group Statistics 
 
SEX N Mean 
Std. 
Deviation 
Std. Error 
Mean 
PRE-OPERATIVE 
PULMONARY  HT 
1 145 72.15 19.993 1.660 
2 120 69.34 20.756 1.895 
0-MONTHS 
PULMONRY HT 
1 145 45.50 11.775 .978 
2 120 46.77 10.744 .981 
3-MONTHS 
PULMONARY  HT 
1 134 37.56 6.245 .539 
2 117 39.58 8.237 .762 
6-MONTHS 
PULMONARY  HT 
1 134 29.78 5.356 .463 
2 117 30.97 6.515 .602 
 
On analyzing the data the Pulmonary Hypertension was reduced to a mean of 
approximately 46.14mmHG immediately following surgery and significant reduction 
of about 30.38 mmHG after 6 months of surgery. At 3 months follow up the average 
reduction in PHT was about 38.57mmHG .This analysis showed that the reduction in 
PHT had a gradual course after an initial reduction from a mean PHT value of 70.75 
mmHG preoperative values. This gives us a clue that the reduction in Pulmonary 
Hypertension is a gradual one and needed change in organic level as well as in the 
dynamic level which takes some time to achieve.  
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Independent Samples Test 
 t-test for Equality of Means 
df 
Sig.(2-
tailed) 
Mean 
Difference 
PRE OP 
PULMONARY  HT 
Equal variances 
assumed 
263 .264 2.810 
Equal variances not 
assumed 
250.067 .266 2.810 
0-MONTHS 
PULMONRY HT 
Equal variances 
assumed 
263 .364 -1.270 
Equal variances not 
assumed 
260.472 .360 -1.270 
3-MONTHS 
PULMONARY  HT 
Equal variances 
assumed 
249 .028 -2.021 
Equal variances not 
assumed 
214.527 .031 -2.021 
6-MONTHS 
PULMONARY  HT 
Equal variances 
assumed 
249 .111 -1.198 
Equal variances not 
assumed 
224.980 .116 -1.198 
 
On performing the T-test on the given statistics there was a statistical significance in 
patients who had a reduction in Pulmonary Hypertension after 3 months 
postoperatively from the preoperative value. 
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Preoperative Hemodynamic in Patients with Pulmonary Hypertension 
Variable Severe PHT 
Systolic PAP (mm Hg) [range] 84.5 [75–105] 
 
Mean PAP (mm Hg) [range] 70.88 [51–90] 
 
An average systolic pressure of 84.5mmHg and a mean PAP of 70.88 mmHg were 
found in this study. 
 
INTRAOPERATIVE PHT  
S.NO MALE FEMALE 
PAP (MEAN) 62.8mmHg 73.6 mmHg 
 
An average mean PAP of 62.8mmHg and 73.6mmHg were observed in male and 
female patients respectively with severe Pulmonary Hypertension intraoperatively. 
 
POST MVR PHT (6 MONTHS) 
S.NO MALE FEMALE 
MEAN PAP 30.97mmHg  29.78mmHg 
 
An average 30.97 mmg and 29.78mmHg were recorded as mean PAP in male and 
female patients respectively following Mitral valve replacement after an observation 
of 6 months. 
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PAP AT DAY 0 
S.NO MALE FEMALE 
MEAN PAP 46.77mmHg 45.5mmHg 
At day zero the average reduction in PAP were found to be about 46.77mmHg and 
45.5mmHg in both male and female patients respectively following MVR. This is 
found to be significant observation as the immediate drastic reduction in PHT as we 
expect following valve replacement does not occur as anticipated and gives us obvious 
clues as to the reasons behind the reduction in Pulmonary  arterial pressures. 
IMMEDIATE POSTOPERATIVE DEATH 
S.NO MALE FEMALE 
DEATH 04 10 
An average of 7.07 %% of death in this study showed death in the immediate 
postoperative period which includes day 0 and day 1in patients with severe Pulmonary  
Hypertension . 
 
MEAN ACC TIME AND CPB TIME 
S.NO ACC CPB 
LEFT ATRIAL 
APPROACH 
56.6MINS 84 .56 MINS 
SEPTAL APPROACH 68.2 MINS 100.68MINS 
 
This table shows the average Aortic Cross Clamp time and Cardiopulmonary Bypass 
Time needed for the procedure. It is evident from the table that the septal approach 
takes a longer ACC and CPB time on comparison. 
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In all the 265 patients who underwent MVR, 195 of them had severe Pulmonary 
Hypertension. All of them had the classical left atrial approach through Sondergaard’s 
groove incision except 11 cases which was approached through the septum after 
opening the right atrium. 
All cases were opened through the standard median sternotomy and were done using 
cardiopulmonary bypass utilizing cardioplegic arrest to open the chamber (s). 
In about 195 out of 265 patients (73.58%), MVR was done with either partial are 
complete chordal preservation. All the patients had St Jude’s valve placed as the 
mechanical prosthetic valve. Except for the 14 deaths which occurred due to low 
cardiac output failures all other cases were weaned of the ventilator by day 1 and from 
the inotropic supports by day 2 or day 3. 
 
Those patients who had severe Pulmonary  Hypertension who underwent MVR were 
followed up using echo at day 0 ,3 months and 6 months later and results thus 
obtained showed an early reduction in about  21.16% of males and 27.35% of females 
.About 79.84% of male patients and 72.65% of female patients showed a  trend of 
reduction in Pulmonary  Hypertension in about 3- 6 months time as compared to those 
patients who showed  an immediate reduction in Pulmonary  Hypertension following 
mitral valve replacement for mitral valvular heart disease with severe Pulmonary  
Hypertension . 
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Discussions 
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DISCUSSION 
 Pulmonary Hypertension (PH or PHT) is an increase in blood pressure in the 
Pulmonary artery, Pulmonary vein, or Pulmonary capillaries, together known as the 
lung vasculature, leading to shortness of breath, dizziness, fainting, and other 
symptoms, all of which are exacerbated by exertion. Pulmonary Hypertension can be a 
severe disease with a markedly decreased exercise tolerance and heart failure. It was 
first identified by Dr. Ernst von Romberg in 1891. According to the most recent 
classification, it can be one of five different types: arterial, venous, hypoxic, 
thromboembolic or miscellaneous 
 
SIGNS AND SYMPTOMS 
Because symptoms may develop very gradually, patients may delay seeing a physician 
for years. Common symptoms are shortness of breath, fatigue, non-productive cough, 
angina pectoris, fainting or syncope, peripheral edema (swelling around the ankles and 
feet), and rarely hemoptysis (coughing up blood). 
Pulmonary venous hypertension typically presents with shortness of breath while 
lying flat or sleeping (orthopnea or paroxysmal nocturnal dyspnea), while Pulmonary 
arterial hypertension (PAH) typically does not. 
 
DIAGNOSIS 
 A physical examination is performed to look for typical signs of Pulmonary 
Hypertension, including a loud P2 (pulmonic valve closure sound), (Para) sternal 
heave, jugular venous distension, pedal edema, ascites, hepatojugular reflux, clubbing 
etc. Evidence of tricuspid insufficiency is also sought and, if present, is consistent 
with the presence of Pulmonary Hypertension. 
Investigations include apart from the blood routine, an ECG, Echocardiogram to 
confirm diagnosis and quantify the severity, x-ray chest which shows the classical 
picture of dilated and prominent Pulmonary arteries with obliterated left cardiac 
shadow with straightening of left cardiac border. Arterial blood gas analysis or simple 
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bedside 02 saturation may give us the clue for the diagnosis. Biopsy of the lung is 
usually not indicated unless the Pulmonary Hypertension is thought to be due to an 
underlying interstitial lung disease. But lung biopsies are fraught with risks of 
bleeding due to the high intrapulmonary blood pressure. Blood BNP level is also 
being used now to follow progress of patients with Pulmonary Hypertension.  
 
Cardiac catheterization is not routinely done nowadays to quantify Pulmonary 
Hypertension as newer Echocardiography studies throw us sufficient lights for the 
evidence and measurement of Pulmonary Hypertension. 
 
Normal Pulmonary arterial pressure in a person living at sea level has a mean value of 
12–16 mm Hg (1600–2100 Pa). Pulmonary Hypertension is present when mean 
Pulmonary artery pressure exceeds 25 mm Hg (3300 Pa) at rest or 30 mm Hg (4000 
Pa) with exercise. 
Mean Pulmonary artery pressure (mPAP) should not be confused with systolic 
Pulmonary artery pressure (sPAP), which is often reported on echocardiogram reports. 
A systolic pressure of 40 mm Hg typically implies a mean pressure more than 25 mm 
Hg. Roughly, mPAP = 0.61•sPAP + 2. 
Vascular resistance is a term used to define the resistance to flow that must be 
overcome to push blood through the circulatory system. The resistance offered by the 
peripheral circulation is known as the systemic vascular resistance (SVR), while the 
resistance offered by the vasculature of the lungs is known as the Pulmonary vascular 
resistance (PVR).  
Units for measuring vascular resistance are dynes·s·cm-5 or Pascal seconds per cubic 
meter (Pa.s/m³). Pediatric cardiologists use hybrid reference units (HRU), also known 
as Wood units, as they were introduced by Dr. Paul Wood. To convert from 
dynes·s·cm-5 to Wood units you must divide by 80.  
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Normal Values For Vascular Resistance 
Systemic vascular resistance 1170 ± 270 dynes·s·cm-5 117  ± 27 MPa.s/m³
Systemic vascular resistance index 2130 ± 450 dynes·s·cm-5·m2 213  ± 45 MPa.s/m 
Pulmonary  vascular resistance 67 ± 30 dynes·s·cm-5 6.7 ±   3 MPa.s/m³ 
 
1 Calculation of resistance 
The basic tenet of calculating resistance is that flow is equal to driving pressure 
divided by resistance. 
 
CAUSES AND CLASSIFICATION 
A 1973 meeting organized by the World Health Organization was the first to attempt 
classification of Pulmonary Hypertension. A distinction was made between primary 
and secondary PH, and primary PH was divided in the "arterial plexiform", "veno-
occlusive" and "thromboembolic" forms. A second conference in 1998 at Évian-les-
Bains also addressed the causes of secondary PH (i.e. those due to other medical 
conditions), and in 2003, the 3rd World Symposium on Pulmonary  Arterial 
Hypertension was convened in Venice to modify the classification based on new 
understandings of disease mechanisms. The revised system developed by this group 
provides the current framework for understanding Pulmonary Hypertension. The 
system includes several improvements over the former 1998 Evian Classification 
system. Risk factor descriptions were updated, and the classification of congenital 
systemic-to Pulmonary shunts was revised. A new classification of genetic factors in 
PH was recommended, but not implemented because available data were judged to be 
inadequate. 
The Venice 2003 Revised Classification system can be summarized as follows:  
WHO Group I - Pulmonary arterial hypertension (PAH)  
Idiopathic (IPAH)  
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Familial (FPAH)  
 
Associated with other diseases (APAH): collagen vascular disease (e.g. scleroderma), 
congenital shunts between the systemic and Pulmonary circulation, portal 
hypertension, HIV infection, drugs, toxins, or other diseases or disorders  
Associated with venous or capillary disease  
WHO Group II - Pulmonary Hypertension associated with left heart disease  
Atrial or ventricular disease  
Valvular disease (e.g. mitral stenosis)  
WHO Group III - Pulmonary Hypertension associated with lung diseases and/or 
hypoxemia  
Chronic obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD)  
Sleep-disordered breathing, alveolar hypoventilation  
Chronic exposure to high altitude  
Developmental lung abnormalities  
WHO Group IV - Pulmonary Hypertension due to chronic thrombotic and/or embolic 
disease  
Pulmonary Embolism in the proximal or distal Pulmonary Arteries  
Embolization of other matter, such as tumor cells or parasites  
WHO Group V - Miscellaneous  
PATHOGENESIS 
Whatever the initial cause, Pulmonary arterial hypertension (WHO Group I) involves 
the vasoconstriction or tightening of blood vessels connected to and within the lungs. 
This makes it harder for the heart to pump blood through the lungs, much as it is 
harder to make water flow through a narrow pipe as opposed to a wide one. Over time, 
the affected blood vessels become both stiffer and thicker, in a process known as 
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fibrosis. This further increases the blood pressure within the lungs and impairs their 
blood flow. In addition, the increased workload of the heart causes thickening and 
enlargement of the right ventricle, making the heart less able to pump blood through 
the lungs, causing right heart failure. As the blood flowing through the lungs 
decreases, the left side of the heart receives less blood. This blood may also carry less 
oxygen than normal. Therefore it becomes harder and harder for the left side of the 
heart to pump to supply sufficient oxygen to the rest of the body, especially during 
physical activity. 
Pathogenesis in Pulmonary venous hypertension (WHO Group II) is completely 
different. There is no obstruction to blood flow in the lungs. Instead, the left heart fails 
to pumps blood efficiently, leading to pooling of blood in the lungs. This causes 
Pulmonary edema and pleural effusions. 
In hypoxic Pulmonary Hypertension (WHO Group III), the low levels of oxygen are 
thought to cause vasoconstriction or tightening of Pulmonary arteries. This leads to a 
similar pathophysiology as Pulmonary  arterial hypertension. 
In chronic thromboembolic Pulmonary Hypertension (WHO Group IV), the blood 
vessels are blocked or narrowed with blood clots. Again, this leads to a similar 
pathophysiology as Pulmonary arterial hypertension. 
 
TREATMENT 
Treatment is determined by whether the PH is arterial, venous, hypoxic, 
thromboembolic, or miscellaneous. Since Pulmonary venous hypertension is 
synonymous with congestive heart failure, the treatment is to optimize left ventricular 
function by the use of diuretics, beta blockers, ACE inhibitors, etc., or to 
repair/replace the mitral valve or aortic valve. 
In PAH, lifestyle changes, digoxin, diuretics, oral anticoagulants, and oxygen therapy 
are considered conventional therapy, but have never been proven to be beneficial in a 
randomized, prospective manner. 
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A number of agents has recently been introduced for primary and secondary PAH. 
The trials supporting the use of these agents have been relatively small, and the only 
measure consistently used to compare their effectivity is the "6 minute walking test". 
Many have no data on mortality benefit or time to progression.  
  
VASOACTIVE SUBSTANCES 
Many pathways are involved in the abnormal proliferation and contraction of the 
smooth muscle cells of the Pulmonary arteries in patients with Pulmonary arterial 
hypertension. Three of these pathways are important since they have been targeted 
with drugs — endothelin receptor antagonists, phosphodiesterase type 5 inhibitors15, 
and prostacyclin derivatives. 
 
Because inexpensive generic drugs for this disease are not widely available, the World 
Health Organization does not include them in its model list of essential medicines. 
 
 PROSTAGLANDINS 
Prostacyclin (prostaglandin I2) is commonly considered the most effective treatment 
for PAH. Epoprostenol (synthetic prostacyclin, marketed as Flolan) is given via 
continuous infusion that requires a semi-permanent central venous catheter. This 
delivery system can cause sepsis and thrombosis. Flolan is unstable, and therefore has 
to be kept on ice during administration. Since it has a half-life of 3 to 5 minutes, the 
infusion has to be continuous (24/7), and interruption can be fatal. Other prostanoids 
have therefore been developed. Treprostinil (Remodulin) can be given intravenously 
or subcutaneously, but the subcutaneous form can be very painful. An increased risk 
of sepsis with intravenous Remodulin has been reported by the CDC. Iloprost 
(Ilomedin) is also used in Europe intravenously and has a longer half life. Iloprost 
(marketed as Ventavis) is the only inhaled form of prostacyclin approved for use in 
the US and Europe. This form of administration has the advantage of selective 
deposition in the lungs with less systemic side effects. Oral and inhaled forms of 
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Remodulin are under development. Beraprost is an oral prostanoid available in Japan 
and South Korea. ENDOTHELIN RECEPTOR ANTAGONISTS 
The dual (ETA and ETB) endothelin receptor antagonist bosentan (marketed as 
Tracleer) was approved in 2001. Sitaxentan, a selective endothelin receptor antagonist 
that blocks only the action of ETA, has been approved for use in Canada, Australia, 
and the European Union, to be marketed under the name Thelin. Sitaxentan has not 
been approved for marketing by the U.S. Food and Drug Administration (FDA). A 
new trial to address the FDA's concerns had begun in 2008. A similar drug, 
ambrisentan is marketed as Letairis in U.S. In addition, another dual/nonselective 
endothelin antagonist, Actelion-1, from the makers of Tracleer, had entered  clinical 
trials in 2008. 
 
PHOSPHODIESTERASE TYPE 5 INHIBITORS 
Sildenafil, a selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5), 
was approved for the treatment of PAH in 2005. It is marketed for PAH as Revatio. 
We had used this medication in about 73 (195) of the patients with severe Pulmonary 
Hypertension in our study. 
ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE 
 
Soluble guanylate cyclase (sGC) is the intracellular receptor for NO. As of April 
2009, the sGC activators cinaciguat and riociguat are undergoing clinical trials for the 
treatment of PAH  
 
Treatment for hypoxic and miscellaneous varieties of Pulmonary Hypertension has not 
been established. However, studies of several agents are currently enrolling patients. 
Many physicians will treat these diseases with the same medications as for PAH, until 
better options become available. Such treatment is called off-label. 
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MONITORING 
Patients are normally monitored through commonly available tests such as: 
¾ Pulse oximetry,  
¾ Arterial blood gas tests,  
¾ Chest X-rays,  
¾ Serial ECG tests,  
¾ Serial echocardiography. 
 
 
In all our 265 patients who underwent MVR 195 had severe Pulmonary Hypertension 
and females 111/195(56.9%) outnumbered the males in this diagnosis. The immediate 
reduction of Pulmonary Hypertension happened in only approximately 21 % of the 
patients and the remaining had persistent PHT which showed a fall progressively 
following a 6 months period suggesting the various factors which might be 
responsible for the Pulmonary Hypertension. 
 
The average mortality noted in this study was comparatively less (7.2%) % than an 
expected value of about 10-15% by the previous studies. The difference might be 
because of the earlier decision to operate upon this severe group before irreversible 
factors sets in and also due to the better intraoperative and postoperative care using 
latest agents so far approved for this purpose. 
 
However the long-term follow up of these patients are needed to conclude firmly 
regarding the use of newer agents used to reduce Pulmonary  Hypertension either 
intraoperatively are postoperatively. 
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17 patients among the total patients required a septal approach due to the concomitant 
presence of tricuspid regurgitation and hence the need for devega procedure done for 
them. 
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CHEST X-RAY OF SEVERE PULMONARY HYPERTENSION
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C 
 
ECHO  DOPPLER PICTURE OF SEVERE PULMONARY HYPERTENSION
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                     EXCISED SPECIMEN OF MITRAL VALVE 
 
 
                     
          DOPPLER IMAGE OF RHEUMATIC MITRAL STENOSIS 
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PRE-CARDIOPULMONARY BYPASS PICTURESHOWING DILATED MAIN  
                                      PULMONARY ARTERY                       
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INTRAOPERATIVE PULMONARY PRESSURE MEASUREMENT  
USING NEEDLE 
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INTRAOPERATIVE PULMONARY PRESSURE RECORDING
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PHOTOGRAPH SHOWING RHEUMATIC MITRAL VALVE EXPOSURE ON 
                                 CARDIOPULMONARY BYPASS
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INTRAOPERATIVE PICTURE SHOWING INSERTION OF St JUDE’S 
       MECHANICAL PROSTHETIC VALVE IN MITRAL POSITION 
  73
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary & Conclusion 
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SUMMARY &CONCLUSION 
Pulmonary arterial hypertension has long been considered a risk factor for poor 
outcome in patients undergoing MVR, with operative mortality ranging from 15%–
31%. Najafi and colleagues found the degree of PAH correlated strongly with 
perioperative mortality, ranging from 16% in patients with mild PAH to 23% in severe 
PAH and 61% when PAP was at systemic levels. Recently, several reports have 
demonstrated improved outcome in patients with PAH undergoing MVR, with 
perioperative mortality ranging from 2.3%–10%.The improved outcome was 
attributed to better myocardial preservation, preservation of the subvalvular apparatus, 
and improved postoperative care. In our study, the overall operative mortality rate was 
7.07 % which is consistent with recent reports. However, the mortality rate in patients 
with PHT overall was 5.5 % which is better than the recent reports.  
Numerous studies have examined hemodynamic changes in this subset of patients at 
different intervals after mitral valve procedures. Most have demonstrated an 
immediate reduction in PAP and PVR, signifying a sudden drop in left atrial pressure 
and reversal of the severe spastic Pulmonary vasoconstriction that accompanies left 
atrial hypertension in some patients. Others have shown slow regression of elevated 
PAP and PVR several months postoperatively. These reports point toward the 
involvement of multiple factors in the development of PAH in mitral valve disease. 
There have been studies of closed mitral commissurotomy and balloon mitral 
valvotomy in this subgroup of patients from India, which have shown good results in 
terms of survival, postoperative functional class, and hemodynamics. In our study the 
mean PAP and PVR did not fall significantly immediately following MVR .The mean 
fall in PAP was about 46.77 % in males and 45.5% in females which was against the 
previous views .Although the mean PAP fell significantly from 84.5 to 70.88%  mm 
Hg, it remained within the definition of severe PAH. The PVR showed no significant 
reduction immediately after MVR, but a gradual regression was seen over a 6 months 
period and the fall was significant at 6 months period when compared with the 
preoperative values. This indicates the reactive component of Pulmonary arterial 
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vasoconstriction, which may be responsible for part of the disproportionate elevation 
of PVR seen in as many as 20% of patients undergoing mitral valve procedures.  
The persistence of residual elevated PAP and PVR well beyond the normal limit in 
patients suggests an irreversible component of the increased PVR. Other variables that 
determine the immediate and long-term results of surgery in this subset of patients 
include advanced age, acute presentation, decreased left ventricular ejection fraction, 
functional class, right heart failure and increased left ventricular end-diastolic 
pressure. Vincens and colleagues identified clinical right heart failure as a predictor of 
operative mortality, and both right ventricular systolic pressure and right ventricular 
hypertrophy as predictors of poor outcome. Others have identified severe tricuspid 
regurgitation and the need for concomitant tricuspid surgery as risk factors for 
operative mortality in this population. In this study, 47% of patients had right 
ventricular hypertrophy and/or dilatation, and 33% had severe tricuspid regurgitation.  
Despite the high operative mortality in most series of MVR in patients with severe 
PAH, a striking improvement in survival was noted. In our series, functional class 
improved by one class or more in the majority of survivors. Long-term morbidity was 
related mainly to anticoagulation and was attributed to poor patient compliance due to 
illiteracy in this part of the world. Repair of the mitral valve in patients with 
predominant MR could have avoided these complications but it was not undertaken 
because of the high rate of repair failure in patients with rheumatic etiology of mitral 
regurgitation as well as severe subvalvular pathology with calcification of leaflets in 
most of them.  
I acknowledge that the lack of follow-up of Pulmonary vascular dynamics by 
catheterization constitutes a limitation of this study and was related primarily to 
economic factors. A postoperative lung biopsy might have added to the information, 
but this was not undertaken as most of the patients refused consent for it.  
 
I conclude that MVR is safe and effective even in the presence of severe PAH as long 
as the Pulmonary  arterial pressures are below systemic pressures. With supra-
systemic PAP, MVR carries a high risk of mortality, and the patient continues to have 
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persistent PAH in the postoperative period. Significant reduction in PHT following 
MVR takes place only gradually and in this study about 6 months period showed a 
decline in PHT as compared to the previous belief of immediate reduction in PHT in 
majority of the patients.  
 
This explains the multifactorial causes of PHT in patients with Rheumatic mitral 
valvular heart disease and severe Pulmonary  Hypertension. 
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PROFORMA 
 
NAME:                                           AGE:          SEX:                                      
 
OCCUPATION:                             DATE OF ADMISSION: 
 
 
 
 
ADDRESS FOR COMMUNICATION:   
 
 
ADMISSION DIAGNOSIS:   MS                  MS+MR                                    MR                       
LA CLOT 
 
 
BRIEF HISTORY              : DOE           ANGINA            PALPITATION               
PND            ORTHOPNOEA       OLIGURIA         PE       
 
 
 
NYHA CLASS         :         1                2             3           4        5 
 
 
RHEUMATIC HEART DISEASE      :               YES               NO   
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H/0 ANTIFAILURE MEDICATION:                 YES               NO 
 
 
GENERAL EXAMINATION   :   HT                WT                    HR                  BP                  
A /ICTERUS/CYANOSIS/PEDAL OEDEMA/JVP 
 
 
CVS EXAMINATION    :   RV IMPULSE               LV IMPULSE              AF   a) 
present b) absent.            
 
HEART SOUNDS          : S1 S2            S1 LOUD    VARIABLE           SOFT  
                                             S3 S4         YES           NO           
                                             P2   LOUD, SOFT 
   
 
CARDIAC MURMERS             : MDM            GRADE 
                                                        PSM             GRADE 
 
RESPIRATORY SYSTEM        : BAE                      ; ADDED SOUNDS               
a) RHONCHI    b) FINE CREPTS 
 
 
ABDOMEN                                  :   HEPATOMEGALY 
                                                           SPLENOMEGALY 
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                                                           ASCITES 
 
CNS                                              : NEUROLOGICAL DEFICIT. 
 
 
INVESTIGATIONS              : BLOOD TC          DC                  ESR                       
PCV               Hb            PL COUNT 
 
 
                                                 BT                CT 
                                         
                               BLOOD UREA                   BLOOD SUGAR                   S. 
CREATININE                  S.          Na             k 
 
                   ECG        RVH           P mitrale            LVH               AF                ST-T 
SEGMENT            OTHERS 
 
 
                                                X-RAY CHEST        :                       
CT RATIO : 
 
  BLOOD GROUPING & Rh Typing 
 
                                               ECHO:   MVO          MVA            LEAFLET             
MOBILITY                  THICKENING      Ca +         SCF 
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 LA SIZE                         PHT   a) mild   b)           moderate                       
c) severe 
 
                                                                 LV DIMENSION                                    EF: 
 
                                               
  CORONARY ANGIOGRAM: 
 
 
 
 
INTRA OP DETAILS: TOTAL CPB TIME               TOTAL 'X ' CLAMP TIME            
CP   1   2    3 4 
 
                                         VALVE SIZE    :  
                                         
 PULMONARY ARTERY PRESSURE SYSTOLE:                      DIASTOLE:            
 
 
 
 
POST OP DETAILS: PULMONARY ARTERY PRESSURE SYSTOLE:                     
DIASTOLE: 
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POSTOP       : VENTILATOR SUPPORT   :   <24 HRS   24-48 HRS                  
48-72 HRS               >72 HRS 
 
 INOTROPES   : DOP/DOB               DOP+DOB                DOP/DOB+ADR/ISO           
OTHERS 
   
 
 COMPLICATIONS               : SSSI                          STERNAL DEHISCENCE                    
LCOS            MODS 
 MORTALITY                         : LCOS                      ARRHYTHMIA                       
SUDDEN CARDIAC ARREST 
 
 
 
 
IMMEDIATE POSTOPERATIVE : PULMONARY  ARTERY PRESSURE   : 
 3 MONTHS    
    
 6 MONTHS 
                                                 
 1 YEAR. 
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MASTER CHART 
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S.No NAME AGE 
AGE 
GROUP* 
DURATION   
SEX SEX** DEATH 
PREOP 
PHT 
(mmHg) 
0 MON 
(mmHg) 
3 MON     
(mmHg) 
6 MON 
(mmHg) 
SEVERITY   
NYHA NYHA*** 
1 GANDHIMATHY 45 4 1 1 0 80 40 35 25 1 2 
2 MD.ALI 27 2 2 2 0 70 38 32 30 1 2 
3 NASRUDEEN 47 4 1 2 0 75 48 30 26 1 2 
4 VARALAXMI 42 4 2 1 0 86 52 40 36 1 2 
5 ANNATHAI 35 3 2 1 0 78 50 44 30 1 1 
6 RAJAMNI 27 2 1 2 0 74 46 40 36 1 2 
7 RAJAMAL 29 2 2 1 0 38 30 26 20 1 1 
8 KARTHIK 25 2 1 2 0 36 30 24 20 1 1 
9 CHANDRA            40 4 2 1 0 88 48 38 30 1 2 
10 NADIYA 18 1 2 1 0 78 44 40 36 1 2 
11 BALA 30 3 3 2 0 90 54 40 36 1 2 
12 MALATHI 20 1 1 1 0 40 32 26 24 1 1 
13 RANI 50 5 2 1 0 86 46 40 30 1 2 
14 RAMAR                24 2 2 2 0 80 50 40 32 1 2 
15 LAKSHMI 45 4 2 1 0 74 46 44 30 1 2 
16 PARTHIBAN         27 2 1 2 0 40 32 30 26 1 2 
17 MARYRANI          35 3 1 1 0 36 30 28 20 1 2 
18 MANJULA 35 3 2 1 0 76 44 40 32 1 2 
19 LAKSMIDEVI        45 4 1 1 0 82 46 40 32 1 2 
20 MANI 45 4 2 2 0 78 52 46 34 1 2 
21 SEKAR 43 4 3 2 0 40 36 30 22 1 2 
22 NAGARAJ            48 4 2 2 1 94 88     0   
23 RADHABAI           49 4 1 1 0 76 48 44 34 1 2 
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24  MANIKANDAN        16 1 3 2 0 40 36 30  28  1  2
25  BALASUBRAMANI              2 27 2 2 2 0 80 56 52  34  1  2
26  RENUKA  20 2 2 1 0 36 30 28  20  1  1
27  SANTHOSH           19 1 2 2 0 68 54 48  40  1  1
28  ELUMALAI  50 5 2 2 0 38 34 30  22  1  2
29  RAMACHANDRA    15 1 2 2 0 88 52 46  38  1  2
30  PONNAMAL           47 4 2 1 0 40 32 30  20  1  2
31  SIVAJIRAO                      4  44 4 1 2 0 78 50 46  38  1  2
32  SAROJA                            4  49 4 2 1 0 34 30 22  20  1  2
33  UMA  38 3 2 1 0 90 40 34  30  1  2
34  MEENAKSI            28 2 1 1 0 88 38 36  26  1  2
35  ANJALI                  30 3 2 1 0 90 48 40  32  1  2
36  THIIRUMATHY       15 1 2 1 0 30 28 24  20  1  2
37  UMAPATHY           45 4 2 2 0 72 56 44  36  1  2
38  INDRANI  34 3 2 1 0 70 44 30  28  1  2
39  SARAVANAN                     2 25 2 2 2 0 40 38 36  30  1  1
40  ANURADHA           32 3 2 1 0 84 44 36  30  1  2
41  MANJULA  43 4 3 1 0 90 48 40  36  1  2
42  KUMAUDHA           21 2 2 1 0 98 46 40  38  1  2
43  EZHIL                                 4  45 4 2 2 0 84 58 50  46  1  2
44  SANGEETHA                     2  22 2 2 1 0 70 40 38  30  1  2
45  KALAIVANI                         2  26 2 2 1 0 82 42 40  30  1  2
46  RAMASAMI            29 2 2 2 0 86 44 38  30  1  2
47  KUMAR                             4  40 4 2 2 0 40 36 30  24  1  2
48  KAVERI  47 4 2 1 0 90 44 38  34  1  2
49  MURUGAN             32 3 1 2 0 70 44 32  30  1  2
50  SUBRAMANI          42 4 2 2 0 78 48 40  32  1  2
51  SHANTHI  45 4 2 1 0 88 40 32  28  1  2
52  MURUGAIAN          52 5 2 2 1 80 74            
53  GOMATHY             40 4 3 1 0 36 30 28  20  1  2
54  AMARAVATHY      45 4 2 1 0 42 36 30  22  1  1
55  PRABU  21 2 1 2 0 78 50 44  32  1  2
56  VEERAMANI          36 3 2 2 0 78 44 38  26  1  3
57  KUMARAN             35 3 2 2 0 42 40 36  20  1  2
58  ANNAKILI               26 2 2 1 0 74 46 42  36  1  2
59  MANI  30 3 1 2 0 80 54 50  38  1  2
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60  NALINI  25  2  1  1  0  76  48  46  32  1  2 
61  SUBAKUTI             30  3  2  2  0  40  36  30  22  1  1 
62  MASTHAN  45  4  2  1  0  78  44  38  36  1  2 
63  JEELAN  40  4  2  2  0  36  34  30  20  1  1 
64  PETER  50  5  2  2  0  40  34  30  20  1  1 
65  SUMATHY  26  2  1  1  0  78  40  34  24  1  2 
66  SHANTHI  34 3 2 1 0 76 44 42 30 1  2 
67  HARI  45 4 2 2 0 36 30 28 20 1  1 
68  KOLA  15 1 2 1 0 72 40 38 26 1  2 
69  MANGAI  35 3 1 1 0 42 36 30 22 1  1 
70  SARASWATHY                  4  45 4 1 1 0 50 48 40 38 1  2 
71  DHANALAKSMI      53 5 2 1 0 30 28 26 20 1  1 
72  MOHAN  39 3 2 2 0 94 56 50 42 1  2 
73  SELVI  43 4 2 1 0 80 42 40 36 1  2 
74  CHANDRASEKAR               4              1  47 4    2 0 88 54 50 34 1  2 
75  NANDHINI  13 1 1 1 0 80 60 48 38 1  3 
76  AMBA  30 3 2 1 0 72 44 40 32 1  2 
77  SHANMUGAVALI              40              4 40 4    1 0 76 40 38 26 1  2 
78  KALA                                 1  18 1 2 1 0 82 40 36 22 1  2 
79  NADHIYA  18 1 2 1 0 70 46 40 32 1  2 
80  DILLIBABU                         4  48 4 2 2 0 42 32 30 24 1  1 
81  VARADHARAJ                  3  39 3 1 2 0 40 34 30 26 1  1 
82  KUMAR  27 2 2 2 0 76 52 48 36 1  2 
83  KALAVATHY          44 4 1 1 0 90 48 42 36 1  2 
84  SILAMBARASAN    27 2 2 2 0 74 52 50 40 1  2 
85  PERUMAYEE         47 4 3 1 0 40 36 30 26 1  1 
86  ALGUMANI             42 4 2 2 0 90 48 40 36 1  2 
87  SHANU  35 3 2 1 0 78 50 46 24 1  2 
88  MUNIAMMAL                42 4 2 1 0 86 48 40 36 1  2 
89  ATHIRUBAN                       3  39 3 2 2 0 78 44 40 32 1  1 
90  NATRAJAN                        2  27 2 1 2 0 30 26 20 18 1  1 
91  RAJAMMAL            45 4 2 1 0 74 40 36 30 1  1 
92  MURUGAN             18 1 2 2 0 78 40 42 32 1  2 
93  VENKATESAN        44 4 2 2 0 80 46 38 26 1  2 
94  DURAISAMI  43 4 2 2 0 40 38 36 24 1  1 
95  GOPI  16 1 1 2 0 80 46 40 38 1  2 
96  ELANGOVAN  39 3 2 2 0 74 50 44 34 1  2 
97  AYYAPAN  33 3 1 2 0 36 30 28 20 1  1 
98  SALEEMA  22 2 1 1 0 40 32 30 24 1  2 
99  ELANGOVAN  39 3 3 2 0 76 54 48 34 1  2 
100  SAHINBEGUM  46 4 2 1 0 80 48 40 34 1  2 
101  SHANTHI  21 2 2 1 0 72 40 36 30 1  2 
102  SELVI  18 1 2 1 0 68 40 38 30 1  2 
103  RAJI  33 3 2 1 0 80 48 40 32 1  2 
104  DHATCHANAMOORTHI  25 2 1 2 0 78 48 44 36 1  2 
105  PARTHASARATHI   35 3 2 2 0 36 30 28 22 1  2 
106  SEKAR  44 4 2 2 0 80 48 40 38 1  2 
107  SHAJIN  46 4 2 1 0 74 48 43 37 1  1 
108  SEKAR  44 4 1 2 0 80 58 48 38 1  2 
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109  SARVANAN  47 4 2 2 0 76 42 38 30 1  2 
110  RAJESVARI  14 1 2 1 0 40 35 28 22 1  2 
111  DEIVANI  52 5 3 1 0 80 48 47 35 1  2 
112  IYYAPAN  20 2 2 2 0 40 30 28 22 1  1 
113  ESAKKIAPPAN      40 4 1 2 0 70 48 40 36 1  2 
114  PONNAN  45 4 2 2 0 80 58 50 36 1  3 
115  LAKSMIDEVI          18 1 2 1 0 70 40 38 33 1  2 
116  SUGANTHI  35 3 2 1 0 76 44 39 27 1  2 
117  NADIYA  26 2 1 1 0 30 26 20 18 1  1 
118  MADAN  15 1 4 2 0 34 30 27 23 1  1 
119  ARUN  23 2 2 2 0 40 36 30 22 1  1 
120  LALITHA  29 2 2 1 0 78 48 40 42 1  2 
121  RANI  28 2 1 1 0 88 40 38 30 1  2 
122  SHANMUGAM  42 4 2 2 0 36 32 30 25 1  1 
123  JANAKIRAMAN  15 1 1 2 0 86 58 50 32 1  2 
124  MAHESVARI  24 2 2 1 0 88 46 40 32 1  2 
125  VATCHALA  59 5 2 1 0 86 44 42 38 1  2 
126  NANDHINI  30 3 2 1 0 38 34 30 24 1  1 
127  GOVINDAN  33 3 2 2 0 88 48 40 37 1  2 
128  MARINESAN  53 5 1 2 0 88 49 47 35 1  2 
129  VASANTHI  30 3 2 1 0 40 38 30 28 1  2 
130  PERIASAMI  49 4 2 2 0 38 32 30 25 1  1 
131  KOLANCHIAPPAN  38 3 1 2 0 90 54 47 33 1  2 
132  VIDHYA  17 1 2 1 0 44 39 27 20 1  1 
133  VASANTHI  25 2 1 1 0 32 30 27 22 1  1 
134  DILIP  23 2 2 2 0 80 49 44 38 1  2 
135  RAMADURAI  36 3 2 2 0 88 49 42 31 1  2 
136  THANGAKODI  61 2 1 1 0 40 38 34 31 1  1 
137  GEETHA  31 3 2 1 0 80 48 40 36 1  2 
138  AYYASAMI  26 2 2 2 0 80 59 47 34 1  2 
139  KESAVAN  37 3 2 2 0 88 53 45 33 1  2 
140  MURUGESAN  36 3 1 2 0 90 56 50 37 1  2 
141  THENMOZHI  38 3 2 1 0 92 46 44 33 1  2 
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142 MURUGAMMAL 20 2 2 1 0 90 56 49 37 1 2 
143 BASKAR 18 1 2 2 0 88 49 43 37 1 2 
144 MINNALKODI 35 3 2 1 0 90 48 42 36 1 2 
145 PANDURANGAN 36 3 2 2 0 40 36 30 24 1 1 
146 SIVAPRAKASH 40 4 2 2 0 32 28 20 18 1 1 
147 DEVI 23 2 1 1 0 86 46 40 38 1 2 
148 SIVAGAMI 40 4 2 1 0 40 32 30 24 1 1 
149 YASODHA 54 5 2 1 0 86 48 40 34 1 2 
150 CHINNARAJ 15 1 2 2 0 46 36 30 22 1 1 
151 SARASWATHY                  4 35 3 1 1 0 94 48 40 32 1 2 
152 RAJA 18 1 2 2 0 90 50 42 36 1 2 
153 SHANTHI 23 2 1 1 0 86 40 36 30 1 2 
154 MARIAMMAL 29 2 2 1 0 88 48 40 36 1 2 
155 SUMITHRA 27 2 1 1 0 90 48 40 36 1 2 
156 LAKSHMI 16 1 2 1 1 88           
157 GOPAL 47 4 2 2 0 40 36 30 22 1 2 
158 SASIKALA 32 3 2 1 0 36 30 28 22 1 1 
159 VIJAYALAKSHMI 14 1 2 1 0 90 46 40 32 1 2 
160 PATCHIAPPAN 38 3 2 2 0 88 58 50 40 1 2 
161 KOUSALYA 31 3 2 1 0 82 46 43 31 1 2 
162 DEVENDRAN 49 4 1 2 0 88 49 41 39 1 2 
163 KANNAN 43 4 2 2 0 70 41 37 26 1 1 
164 RAMALINGAM 40 4 1 2 0 80 47 40 32 1 2 
165 JEYASHANKAR 21 2 2 2 0 78 58 47 32 1 2 
166 GAJALAKSHMI 58 5 2 1 0 32 30 27 22 1 1 
167 RAMASAMI           40 4 1 2 0 70 55 43 31 1 2 
168 KRISNAMOORTHY 49 4 2 2 0 80 44 37 29 1 2 
169 THILLAIAMMAL 28 2 2 1 0 78 49 37 27 1 2 
170 RAJENDREN 38 3 2 2 0 40 32 20 22 1 2 
171 NANDHINI 16 1 2 1 0 86 56 47 32 1 2 
172 ROUTRAJ 32 3 2 1 0 70 46 41 28 1 2 
173 SATHYA 34 3 2 1 0 38 36 34 30 1 2 
174 JEYARAMAN 62 5 3 2 0 82 56 49 37 1 2 
175 RAMACHANDRAN 22 2 2 2 0 90 59 44 32 1 2 
176 KRISNAMOORTHY 48 4 2 2 0 40 36 32 22 1 2 
177 DHANALKSHMI 32 3 2 1 0 90 46 42 36 1 2 
178 VIMALA 42 4 2 1 1 90           
179 SAMINATHAN 40 4 1 2 0 76 54 49 32 1 2 
180 PARI 32 3 2 2 0 88 48 39 21 1 2 
181 VELAYUTHAN 35 3 2 2 0 80 46 40 36 1 2 
182 MAALIGA 34 3 2 1 1 90           
183 JEYACHANDRAN 16 1 2 2 0 80 54 49 37 1 2 
184 ADAIKALARAJ 24 2 2 2 0 88 48 45 36 1 2 
185 MARIAMMAL 17 1 2 1 0 78 46 40 34 1 2 
186 RENUKADEVI 20 2 2 1 0 80 47 39 31 1 2 
187 SATHYA 18 1 2 1 1 88           
188 RAVI 38 3 1 2 0 90 58 50 42 1 2 
189 PALANIAMMAL 37 3 2 1 0 88 48 39 27 1 2 
190 LATHA 31 3 2 1 0 80 42 40 27 1 2 
  94
191 SARAVANAN                     1 14 1 2 2 0 36 30 28 22 1 1 
192 BALAMANI 27 2 2 1 0 80 44 40 28 1 2 
193 INDRANI 28 2 2 1 0 88 48 36 32 1 2 
 
195 PANNERSELVAM 48 4 1 2 0 90 55 48 37 1 2
196 DHANASELVI 30 3 2 1 0 82 42 40 35 1 2
197 SUDHA 18 1 2 1 0 90 48 40 36 1 2
198 KABILAN 39 3 2 2 0 84 47 38 32 1 2
199 SHEIK 28 2 2 2 0 70 50 40 32 1 2
200 SENNAMA 40 4 3 1 0 38 32 28 22 1 1
201 JEGANNATHAN 35 3 2 2 0 90 57 46 37 1 2
202 TAMILSELVI 36 3 2 1 0 40 36 32 28 1 1
203 PARVATHAM 40 4 2 1 0 86 46 40 32 1 2
204 MUNEESHVARI 35 3 2 1 0 86 46 40 34 1 2
205 MUNUSWAMI 27 2 2 2 0 90 59 47 35 1 2
206 SAMINATHAN 40 4 2 2 0 88 56 47 34 1 2
207 SHANTHI 37 3 1 1 0 38 32 30 24 1 1
208 KOMALA 30 3 1 1 1 40           
209 MURUGESVARI 32 3 2 1 0 80 46 39 32 1 2
210 BALAJI 19 1 2 2 0 78 44 40 32 1 2
211 VENKATESAN       24 2 2 2 0 40 38 33 27 1 1
212 NABISHA 47 4 2 1 0 80 48 39 31 1 2
213 EZHILRANI 28 2 2 1 0 80 56 48 36 1 2
214 KAVITHA 30 3 2 1 0 38 30 28 20 1 1
215 KRISHNAVENI 32 3 2 1 1 90 88         
216 MUTULAXMI 35 3 2 1 1 90 80         
217 VINOTHA 22 2 2 1 1 88 80         
218 RAVIKUMAR 47 4 1 2 0 30 28 26 21 1 1
219 SOUNDARYA 28 2 2 1 0 80 48 42 32 1 2
220 ARJUNAN 16 1 2 2 0 40 36 30 26 1 2
221 DURAISAMI 42 4 2 2 0 88 50 46 31 1 2
222 MALARKODI 31 3 2 1 0 80 42 40 32 1 1
223 KARTHIK 39 3 2 2 0 90 48 36 25 1 2
224 KIRTHIHA 17 1 2 1 0 88 42 40 28 1 2
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225 SUDHA 28 2 1 1 1 90 76       
226 VENKATESAN       22 2 2 2 0 78 56 50 35 1
227 PALANI 32 3 2 2 0 40 36 30 32 1
228 PARVATHI 40 4 2 1 0 88 44 40 32 1
229 SELVAMARI 28 2 2 1 0 78 42 40 32 1
230 SUDHA 28 2 2 1 0 40 36 30 22 1
231 SHNTHAKUMARI 40 4 2 1 0 34 32 28 22 1
232 SHANMUGAM 51 5 2 2 0 88         
233 ANJALAIDEVI 26 2 2 1 0 88 50 46 32 1
234 KASTHURI 30 3 2 1 0 78 48 40 32 1
235 KANNIAPPAN 36 3 2 2 0 90 56 50 40 1
236 PALANISAMI 40 4 2 2 0 40 34 32 30 1
237 ABITHA 25 2 1 1 0 90 50 48 32 1
238 GOMATHY            30 3 2 1 0 9048 40 30 26 1
239 JADAMANI 36 3 2 2 0 80 50 44 32 1
240 CHANDRAMATHI 32 3 2 1 0 88 50 47 34 1
241 MUTHU 40 4 2 2 0 80 54 42 36 1
242 SIVAGAMAI 40 4 2 1 0 80 46 42 34 1
243 PRABHU 35 3 2 2 0 90 58 50 32 1
244 SADASIVAM 45 4 1 2 0 78 56 46 32 1
245 EDWARD 58 5 2 2 0 80 48 40 28 1
246 SUGANTHI 17 1 2 1 0 88 48 46 38 1
247 SARALA 23 2 2 1 0 90 42 38 27 1
248 RATHINAVELU 54 5 2 2 0 86 46 40 32 1
249 SARASWATHY                  4 23 2 2 1 0 78 46 40 27 1
250 PALANIAMMAL 45 4 2 1 0 70 48 40 34 1
251 SANGEETHA                    2 19 1 2 1 0 70 48 40 36 1
252 SNEHA 18 1 2 1 0 90 59 48 31 1
253 SANGEETHA                     2 20 2 2 1 0 72 48 40 28 1
254 SUMATHY 35 3 2 1 1 82         
255 SAMUNSEHVARI 15 1 1 1 0 78 48 42 28 1
256 SHANKAR 13 1 1 2 0 80 58 50 45 1
257 MAHESHVARI 35 3 2 1 1 90 80       
258 CHITRA 24 2 2 1 0 90 47 36 28 1
259 KAVITHA 25 2 2 1 0 38 36 32 30 1
260 JANAKI 33 3 2 1 0 80 50 42 34 1
261 LAKSHMI 26 2 2 1 0 40 32 30 22 1
262 MUNUSWAMI 35 3 2 2 0 90 54 48 35 1
263 AYYANAR 35 3 2 2 0 86 54 50 40 1
264 GOPALAKRISHNAN 42 4 1 2 0 86 52 48 32 1
265 VIJAYA 37 3 2 1 0 80 56 48 32 1
            
 * Age Group  ** Sex  ***NYHA       
 1- 10-19 years  1- Female  1- Class I       
 2- 20-29 years  2-Male  2-Class II       
 3-30-39 years    3-Class III       
 4- 40-49 years           
 5-> 50 years           
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Rheumatic Heart disease has been one of the major health problems in developing 
countries like India. This is an autoimmune disease which occurs in the cardiac tissues 
due to streptococcal throat infection. Pancarditis and particularly vasculitis contributes 
the major complication following this disease. Mitral valve constitutes about 50 % of 
the valve which gets affected due to rheumatic heart disease. Pulmonary Hypertension 
is said to complicate about 70% of the patients affected by this disease. Pulmonary 
Hypertension adversely affects the prognosis and course of the disease. 
Pulmonary Hypertension in mitral valvular heart disease leads to various adverse 
outcome following surgical treatment of this condition. In majority of the patients this 
Pulmonary Hypertension is reversible following surgery. In considerable number of 
patients however the persistence of Pulmonary Hypertension leads to postoperative 
problems which may result in death. 
 
Understanding the Pathophysiology of the Pulmonary  Hypertension occurring due to 
this disease and analyzing it before embarking on the treatment option would largely 
benefit the team involved in the care of suffering patients. 
Management of Pulmonary Hypertension before surgery involves investigations and 
manipulation with certain drugs which may reduce the Pulmonary pressures before 
proceeding towards surgical correction. 
 
An attempt of a prospective study to analyze the facts is made and the results are 
tabulated and compared to the national and international views on the same parameter 
of this common disease.  
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Pulmonary Hypertension is diagnosed clinically by identifying loud P2 component of 
2nd Heart sound, TR Murmur and the accompanying ECG changes  
 
like Right Atrial enlargement, Right Axis deviation and electrical rotation of the 
Heart.  
Pulmonary Hypertension is readily identified by Echocardiography which is also used 
to classify the pressures into mild, moderate and severe categories. Catheterization 
studies are not done routinely as echocardiogram has emerged as an effective tool to 
identify Pulmonary Hypertension and classify accordingly. 
In our study which was conducted for a period of 2 years from July 2007 to July 2009 
we had recorded data of about 265 patients with Mitral Stenosis or Mitral 
Regurgitation cases with severe Pulmonary Hypertension. We had investigated them 
with preoperative ECHO and introperative PAP measurement using transducers and 
followed them with postoperative Echocardiogram for about 6 months. 
All patients were well informed about the procedure and appropriate consent had been 
obtained prior to the valve replacement. 
The results obtained from the data collection were tabulated and analyzed using 
various parameters which may affect the outcome of the patients and were statistically 
scrutinized using appropriate software. 
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REVIEW OF LITERATURE 
 
PULMONARY  HYPERTENSION -MECHANISM 
Patients with Rheumatic Heart Disease develop Pulmonary Hypertension due to 
various reasons and prime cause among them will be the retrograde transmission of 
LA Hypertension which gets transmitted to the Pulmonary arteries. Pulmonary venous 
pressure also is transmitted to Pulmonary arteries. There is also reactive Pulmonary 
Arteriolar constriction which can lead to Pulmonary Hypertension. For some unknown 
reasons there are morphological changes in Pulmonary Vasculature which can lead to 
the development of Pulmonary Hypertension. Interstitial Oedema which can occur due 
to elevated LA pressure >20 mmHg can also lead to the development of Pulmonary 
Hypertension.  
Pathophysiology of Pulmonary Hypertension 
   Elevated LA pressure 
   Elevated Pulmonary venous pressure 
   Transmitted pulmonary venous hypertension to arteries 
   Vasoconstriction of Pulmonary arterioles 
   Pulmonary Artery Hypertension 
   Right ventricular dilatation  
   Tricuspid Regurgitation  
    Right Atrial enlargement 
    Congestive cardiac failure  
 
The above flow chart explains the Pathophysiology of Pulmonary Hypertension in 
Mitral Valvular heart disease in both Rheumatic Mitral Stenosis and Regurgitation. 
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Pulmonary Hypertension greatly influences the natural course of the disease process, 
treatment response and also the post intervention prognosis. 
Wood et al had noted that severe PHT was associated with both moderate MS and 
severe MS. Fawzy and Reibero pointed out that there is another group of patients with 
severe MS, yet only a mild increase in PAP. The reasons for not developing PHT in 
these cases are not clear. No significant relation between LA size and PAP has been 
noted. There is a view that the increase in LA size would cushion of the sequelae of 
increase in pressure. 
 
Bahl et al and Krishnamoorthy et al had observed that PHT is an indicator of disease 
severity in patients with Mitral Stenosis. Chronicity of the disease process as indicated 
by the presence of severe fibrosis and Atrial Fibrillation are important in the 
development of reactive PHT  
 
FEATURES INDICATING SEVERITY OF DISEASE IN MITRAL 
VALVULAR LESIONS COMPLICATED BY PULMONARY 
HYPERTENSION 
¾ Severe Subvalvular Pathology 
¾ Small Mitral Valve Area 
¾ Higher Transvalvular gradient 
¾ Higher Pulmonary  valve resistance 
¾ Higher NYHA symptoms 
¾ Thickened non pliable valves 
¾ Higher Wilkins score 
¾ Higher incidence of Atrial Fibrillation. 
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DEFINITION: 
In medicine, Pulmonary  Hypertension (PH or PHT) is an increase in blood pressure 
in the Pulmonary  artery, Pulmonary  vein, or Pulmonary  capillaries, together known 
as the Lung Vasculature, leading to shortness of breath, dizziness, fainting, and other 
symptoms, all of which are exacerbated by exertion. Pulmonary Hypertension can be a 
severe disease with a markedly decreased exercise tolerance and heart failure. It was 
first identified by Dr. Ernst von Romberg in 1891 
The Venice 2003 revised classification system can be summarized as follows. 
WHO Group I - Pulmonary Arterial hypertension (PAH)  
Idiopathic (IPAH)  
Familial (FPAH)  
Associated with other diseases (APAH): Collagen Vascular Disease (e.g. 
Scleroderma), congenital shunts between the systemic and Pulmonary Circulation, 
portal hypertension, HIV infection, drugs, toxins, or other diseases or disorders  
Associated with venous or capillary disease  
WHO Group II - Pulmonary Hypertension associated with left heart disease  
Atrial or Ventricular disease  
Valvular disease (e.g. Mitral Stenosis)  
WHO Group III - Pulmonary Hypertension associated with lung diseases and/or 
Hypoxemia  
Chronic Obstructive Pulmonary disease (COPD), Interstitial Lung Disease (ILD)  
Sleep-disordered breathing, Alveolar Hypoventilation  
Chronic exposure to high altitude  
Developmental lung abnormalities  
WHO Group IV - Pulmonary Hypertension due to chronic thrombotic and/or embolic 
disease  
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Pulmonary Embolism in the proximal or Distal Pulmonary Arteries  
Embolization of other matter, such as tumor cells or parasites  
WHO Group V - Miscellaneous  
This Classification does not include sickle cell disease, Human Herpesvirus 8, also 
associated with Kaposi's sarcoma, and has been demonstrated in patients with PAH, 
suggesting that this virus may play a role in its development. Recent studies have been 
unable to find an association between human Herpesvirus 8 and Idiopathic Pulmonary 
Arterial Hypertension. 
 
Pulmonary Hypertension – Heath Edwards grading system 
Grade Microscopic Features 
Potentially Reversible 
I 
Hypertrophy of the media of muscular Pulmonary Arteries. Extension of 
muscle into the wall of Pulmonary Arterioles. 
II 
Muscle Hypertrophy plus proliferation of intimal cells in arterioles and 
small muscular arteries. 
III 
"Muscle hypertrophy plus sub endothelial fibrosis. Eventually, concentric 
masses of fibrous tissue and reduplicated internal elastic lamina occlude the 
vascular lumen of arterioles and small muscular arteries. Large elastic 
arteries show atherosclerosis." 
  110
 
Grade Microscopic Features 
Usually Irreversible 
IV 
"Muscle hypertrophy is less apparent; progressive dilatation of small 
arteries, especially those near vessels with Intimal fibrous occlusion. 
Plexiform lesions occur." 
V 
Plexiform and Angiomatoid lesions plus intra-alveolar Hemosiderin-filled 
macrophages. 
VI 
Necrotizing Arteritis with thrombosis. Fibrinoid necrosis of the arterial wall 
with a Transmural infiltrate of Polymorphonuclear leukocytes and 
Eosinophils. 
Usually Pulmonary Hypertension grade 3 and below are reversible and can be taken 
up for surgery with better results. Pulmonary Hypertension grade 4 and above has 
significant contribution for postoperative morbidity and mortality. 
 
PATHOLOGICAL FINDINGS: 
Pathological changes in lungs in rheumatic MS include prominent vascular and 
parenchymal changes. Pulmonary veins develop muscular media. Moderate to marked 
medial hypertrophy occurs in medium sized branches of the Pulmonary arteries. 
Dilatation lesions and plexiform lesions are rarely seen in rheumatic MS .Tandon et al 
and Chopra et al has reported such lesion in 4% of the autopsy studies conducted in 
New Delhi, India. Mubeen et al, recently has reported that Pulmonary vascular 
changes do not go beyond grade 3 (Heath Edward) criteria in RHD. The most striking 
feature seen is prominent smooth muscle layer in Bronchoalveolar walls. The extent 
and severity of both vascular and parenchymal changes are seen more in juvenile MS. 
Haemosiderosis has been reported in long standing cases. 
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TREATMENT OPTIONS: 
¾ MEDICAL  
¾ INTERVENTIONAL 
¾ SURGICAL  
 
MEDICAL: 
Patients with Mitral Valvular heart disease and PHT are started with rate controlling 
drugs and diuretics once they become symptomatic. Rate controlling drugs like Beta-
blocker and Calcium channel blockers are started to control AF which otherwise 
would worsen the condition. Rate control with these drugs help in reducing the 
Transmitral gradient and hence the PHT. Digoxin is usually started for the failing 
heart and RV dysfunction which has to pump blood against severe Pulmonary 
Hypertension.  
 
INTERVENTIONAL: 
Isolated MS and PHT were treated by closed Mitral Commisurotmy (CMC) and 
Balloon Mitral Valvotomy (BMV) from time immemorial. Balloon Mitral Valvotomy 
can be attempted only if the valves are pliable and the Wilkins score is favorable. 
There are many concerns before proceeding to BMV like the less tolerance to the 
stress of the procedure, difficulty in negotiating the septum in large right sided 
chambers, Tight Mitral Stenosis and fear of tearing the mitral valve and creating 
Mitral Regurgitation. However the AHA GUIDELINES 2008 clearly states the role of 
BMV in a case of severe PHT associated with rheumatic heart disease. Even though 
BMV has given good results in MS and PHT the mitral valve area remained less on 
comparison with open procedures with reasonable reduction in Pulmonary vascular 
resistance and PAP. 
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SURGICAL: 
Patient’s hemodynamic performance was better following reduction in Pulmonary 
vascular resistance particularly after MVR and valvotomy. Pulmonary Hypertension 
regresses after the transmitral gradient reduced following surgery. Hemodynamic 
studies done in patients who had undergone MVR showed a reversibility of 
Pulmonary Artery Hypertension19. Various options are open for surgical management 
of this condition like Mitral valve replacement (MVR), Closed Mitral Commisurotmy 
and Open Mitral Valvotomy. Mitral Valve Replacement may be done with either 
mechanical prosthetic valve or Bioprosthetic Valve Autologous transfer of Pulmonary 
valve (ROSS II PROCEDURE) has also been done for this condition. 
Cesjnvar8 et al has reported higher early mortality among his series of 382 patients 
who underwent MVR for Mitral Valvular disease with Pulmonary Hypertension. But 
the late mortality was no different among patients with or without Pulmonary 
Hypertension. Aris9 et al has confirmed this finding with his series of 88 patients. 
Perioperative mortality with patients having Suprasystemic Pulmonary Arterial 
pressures were 5 times more than with normal or sub systemic pressures. 
In view of this fact subjecting patients with Mitral Valvular heart disease for earlier 
surgical intervention would ameliorate the condition before developing severe 
Pulmonary Hypertension. 
 
PERSISTENT PHT FOLLOWING MVR  
Following MVR majority of the patients have regression of PAP, yet Pulmonary 
Vascular hypertension remains unchanged in significant proportion of patients19. 
Patients with Suprasystemic PAP continue to have persistently elevated PVR. Patients 
with irreversible PHT after MVR are found to have early mortality. Compared to 
patients who have AF, regaining sinus rhythm after MVR results in reduction in PAP. 
Patient –prosthetic mismatch contributes significantly to the persistence of Pulmonary 
Hypertension after MVR. Recent studies had demonstrated the correlation between   
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persistent PHT and patient –prosthesis mismatch and associated poor prognosis. 
Patient –prosthesis mismatch occurs with both mechanical and Bioprosthesis Valves. 
 
TRICUSPID REGURGITATION AND PHT  
Functional TR occurs following severe PHT in a Rheumatic Mitral Valvular heart 
disease. There are conflicting reports regarding the resolution of TR following Mitral 
Valve Replacement. Persistence of TR may contribute to the mortality and morbidity 
following surgeries done for mitral valve disease. Some times simultaneous TR repair 
is recommended during surgeries done for mitral valve disease. Patients with severe 
PHT show regression of TR following MVR and other surgeries for mitral valve 
disease.  
 
PERIOPERATIVE MANAGEMENT OF PHT PATIENTS 
Perioperative mortality is higher with patients having severe PHT and mitral valvular 
heart disease. But late survival curves are similar for patients with or without 
Pulmonary Hypertension, therefore effective perioperative management of severe 
Pulmonary Hypertension would help in the late survival of these patients and there 
would be no significant difference in the Kaplan-Meier survival curves. 
Various drugs are available for managing these patients perioperatively like milrinone, 
nesiridite, inhaled nitric oxide and prostacyclin and on the horizon we also have 
sildanefil and endothelin antagonist like bosentan etc which  has  been  used  both 
preoperatively  and  postoperatively . 
Role  of  phenoxybenzamine  has  been  found  be  useful  in  cases  of  Pulmonary  
Hypertension  secondary  to  congenital  heart  disease  and  in  the  peri  and 
postoperative  periods  of  congenital  heart  disease  correction  especially  with 
elevated  Pulmonary   vascular  resistance . 
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TREATMENT TARGETED AT PULMONARY VASCULATURE 
 
So far traditionally treatment for mitral valvular heart disease focused only on cardiac 
physiology. Now the recent concepts are focusing more in the Pulmonary Vascular 
physiology following mitral valve disease and are due to the renewed interest in 
Cardio Pulmonary Hemodynamics.  Madden15 et al has recently found the role of 
phosphodiesterase 5 inhibitor (sildenafil) in a study conducted by him and found to 
have a positive role in treating these patients. The therapy has been found to be 
significantly tolerated and results are good as early as 8 weeks .Even exercise 
tolerance seems to be improved with this   medicine. 
 
PULMONARY VASCULAR RESISTANCE 
Pulmonary vascular resistance has two components an organic element and dynamic 
element. Dynamic component is relieved immediately following reduction of LA 
pressures. Organic element due to changes in Pulmonary vascular changes regresses 
immediately or may take a long time to do. Kaul and colleagues reported on 30 
patients with severe Pulmonary Hypertension which showed striking regression from 
a mean of 74mm Hg. Restudy an average of 5.5 years after MVR showed an average 
systolic pressure of 48mmHg and mean of 31 mmHg. This drop was largely due to 
sudden reduction of LA pressure and reversal of severe spastic Pulmonary 
vasoconstriction that accompanies left Atrial Hypertension. These changes in 
Pulmonary vascular resistance are a progressive regression and are the same for both 
stenosis and regurgitation. In older patients and in patients with AF the regression 
occurs less frequently. 
 
CALCULATION OF PULMONARY  ARTERY PRESSURE 
Using  Doppler  we  can  measure  the  Pulmonary   artery  pressure  using  the peak  
Transtricuspid  flow  velocity   (VMAX). 
PAP   = 4V max2 + RIGHT ATRIAL PRESSURE. 
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RAP  is  usually  equal  to  jugular  venous  pressure  measured  clinically  or  from  
the  Inferior  Vena  Cava  diameter  measured  in  Expiration   and  percentage  
collapse  of  IVC  in   Inspiration   . 
 
MITRAL STENOSIS 
The mitral valve is made up of the annulus, anterior and posterior leaflets, and 
chordae, which attach the leaflets to their respective papillary muscles. A normally 
functioning valve allows blood to flow unimpeded from the left atrium to the left 
ventricle during diastole and prevents regurgitation during systole. Normal mitral 
valve function is dependent not only on the integrity of the underlying valvular 
structure, but on that of the adjacent myocardium as well. 
 
Definition and Causes 
Mitral stenosis (MS) refers to narrowing of the mitral valve orifice, resulting in 
impedance of filling of the left ventricle in diastole. It is usually caused by rheumatic 
heart disease. Less common causes include severe calcification of the mitral annulus, 
infective endocarditis, systemic lupus erythematosus, rheumatoid arthritis, and 
carcinoid heart disease. 
 
Pathophysiology and Natural History 
Patients with MS typically present more than 20 years after an episode of rheumatic 
fever. Single or recurrent bouts of Rheumatic Carditis cause progressive thickening, 
scarring, and calcification of the mitral leaflets and chordae. Fusion of the 
commissures and chordae decreases the size of the mitral opening. This obstruction 
results in the development of a pressure gradient across the valve in diastole and 
causes an elevation in left atrial and Pulmonary venous pressures. Elevated left atrial 
pressures lead to left atrial enlargement, predisposing the patient to Atrial Fibrillation 
and Arterial Thromboembolism. Elevated Pulmonary Venous pressure results in 
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Pulmonary Congestion and Pulmonary Edema. In advanced mitral stenosis, patients 
develop Pulmonary Hypertension and right-sided heart failure. 
 
Signs and Symptoms 
Patients with mitral stenosis may present with Exertional Dyspnea, fatigue, atrial 
arrhythmias, embolic events, angina-like chest pain, Hemoptysis, or even right-sided 
heart failure. Previously asymptomatic or stable patients may decompensate acutely 
during exercise, emotional stress, pregnancy, infection, or with uncontrolled atrial 
fibrillation. 
The characteristic findings of MS on auscultation are an accentuated first heart sound, 
an opening snap, and a mid-diastolic rumble. The first heart sound may be diminished 
in intensity if the valve is heavily calcified, with limited mobility. If the patient is in 
sinus rhythm, there is presystolic accentuation of the murmur during atrial contraction. 
With increasingly severe stenosis, the duration of the murmur increases and the 
opening snap occurs earlier during diastole as a result of higher left atrial pressure. 
There is accentuation of P2 when Pulmonary Hypertension is present. If flow across 
the mitral valve is reduced because of heart failure, Pulmonary Hypertension, or aortic 
stenosis the murmur of mitral stenosis may be reduced in intensity or may be 
inaudible. 
Left Atrial Myxoma may be distinguished from MS by the presence of a “tumor plop” 
versus an opening snap in early diastole. 
 
Diagnosis 
On chest radiography, the characteristic findings of mitral stenosis are pulmonary 
congestion, enlargement of the main Pulmonary arteries, and enlargement of the left 
atrium without cardiomegaly. An electrocardiogram (ECG) may reveal evidence of 
left atrial enlargement, Atrial Fibrillation or, in advanced disease, right ventricular 
hypertrophy consistent with Pulmonary Hypertension. 
  118
Two-dimensional (2D) and Doppler echocardiography is indicated for all patients with 
suspected MS to confirm the diagnosis and determine its severity (Class I indication). 
Characteristic findings of MS include valve thickening, restricted valve opening, 
anterior leaflet doming, and fusion of the leaflets at the commissures. The mean 
pressure gradient across the mitral valve on Doppler echocardiography (echo) in MS 
is at least 5 mm Hg; in severe stenosis, it is usually higher than 10 mm Hg. Because 
the gradient across the mitral valve is flow dependent, the severity of MS is more 
accurately defined by the mitral valve area (MVA). The normal valve area is 4 to 5 
cm2. In mild mitral stenosis, the MVA is 1.5 to 2 cm2, in moderate stenosis it is 1 to 
1.5 cm2, and in severe stenosis it is less than 1 cm2. The valve area may be measured 
by tracing the mitral valve opening in cross section by 2D echo. Alternatively, the 
MVA is calculated using the pressure half-time (P ×-½t), which is the amount of time 
it takes for the transmitral pressure to fall to one half its initial value (MVA = 220/[P 
×- ½t]).  
 
Echocardiography also allows assessment of Pulmonary artery pressures, detection of 
other valve disease, visualization of left atrial thrombus, and identification of 
important differential diagnoses, such as Left Atrial Myxoma. Tran esophageal echo is 
superior to transthoracic echo at identifying left atrial thrombus in patients who are 
being considered for Percutaneous Mitral Balloon Valvotomy or Cardio Version. 
Stress echocardiography may be helpful if there is a discrepancy between a patient's 
severity of symptoms and the baseline hemodynamic data. An exercise mean 
transmitral gradient of more than 15 mm Hg and peak right ventricular systolic 
pressure of more than 60 mm Hg indicate hemodynamically significant MS. 
Cardiac catheterization is not necessary in all cases but, like stress echocardiography, 
may be helpful in characterizing the severity of mitral stenosis when there is a 
discrepancy between symptoms and findings on echocardiography. 
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Treatment 
Medical Treatment  
Medical therapy has no role in altering the natural history or delaying the need for 
surgery in patients with MS. Medical treatment is directed toward alleviating 
Pulmonary Congestion with diuretics, treating Atrial Fibrillation, and anticoagulating 
patients who are at increased risk of arterial embolic events. 
Development of Atrial Fibrillation frequently leads to an acute deterioration in 
patients with mitral stenosis. The rapid ventricular response results in a decrease in the 
diastolic filling time. Beta blockers, calcium channel blockers, or digoxin may be used 
to control ventricular rate. An attempt to restore sinus rhythm with direct current 
electrical cardioversion or antiarrhythmic drugs may be considered. Anticoagulation 
with warfarin is indicated to prevent thromboembolism when Atrial Fibrillation is 
present, if there is a prior history of thromboembolism, or a thrombus is detected in 
the left atrium (Class I). Although controversial, anticoagulation may also be 
considered if the left atrium is markedly dilated (5.0 to 5.5 mm) or if there is 
spontaneous contrast on echocardiography (Class II b).  
Antibiotic therapy is important for the secondary prevention of Rheumatic Carditis. 
Patients with a history of rheumatic fever are at high risk of recurrence. Long-term 
secondary prophylaxis, preferentially with penicillin, is therefore recommended for all 
patients with a history of rheumatic fever or suspected rheumatic valve disease. The 
duration of prophylaxis depends on a number of factors, including the time lapsed 
since the last attack, the age of the patient, the presence or absence of cardiac 
involvement, and the patient's risk of exposure to streptococcal infections. Routine 
antibiotic prophylaxis for endocarditis is no longer recommended for patients with 
mitral stenosis.  
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Surgery  
Three invasive options are available for patients with MS: (1) Percutaneous Mitral 
Balloon Valvotomy (PMBV); (2) Surgical Mitral Commissurotomy; and (3) Mitral 
Valve Replacement (MVR). In experienced centers, PMBV is the initial procedure of 
choice and should be considered for (1) symptomatic patients (NYHA functional 
Classes II to IV) with moderate or severe MS (Class I) and (2) asymptomatic patients 
with moderate or severe MS and Pulmonary Hypertension (Class I). PMBV is a 
catheter-based technique in which a balloon is inflated across the stenotic valve to 
split the fused commissures and increase the valve area. The MVA typically doubles 
in size, and hemodynamic as well as clinical improvements are seen immediately. The 
results are comparable with those achieved with open Mitral Commissurotomy, but it 
is less invasive and less costly. The Mitral Valve Morphology is an important 
predictor of successful balloon valvotomy. Severe valve calcification or significant 
involvement of the subvalvular apparatus on echocardiography before PMBV is 
associated with a higher complication rate and a greater risk of recurrence. In addition, 
balloon valvotomy should not be performed in patients who have left atrial thrombus 
or more than 2+ (moderate) mitral regurgitation, because the degree of mitral 
regurgitation usually increases following the procedure. Complications of Balloon 
Mitral Valvotomy include severe Mitral Regurgitation (3%), Thromboembolism (3%), 
and residual Atrial Septal Defect with significant shunting (less than 5%). Mortality 
with the procedure is lower than 1% in experienced hands. At 7 years after balloon 
valvotomy, 50% to 69% of patients remain free of cardiovascular events and up to 
90% of patients remain free of reintervention.  However, both Balloon Valvotomy and 
Surgical Commissurotomy are palliative procedures and, in most cases, further 
intervention is eventually required, usually in the form of a Mitral Valve Replacement. 
In patients with calcified valves that cannot be treated by valvotomy or 
commissurotomy, or in those with significant mitral regurgitation that is not suitable 
for repair, mitral valve replacement may be necessary. The threshold for Mitral Valve 
Surgery (commisurotmy or MVR) is higher than for PMBV in patients with Mitral 
Stenosis, and commisurotmy or repair is preferable to MVR, if feasible. Surgery for 
  121
moderate to severe Mitral Stenosis is indicated for symptomatic patients (New York 
heart association [NYHA] functional class iii or iv) where PMBV  is unavailable or 
contraindicated (class i). MVR may also be considered for patients with severe MS 
and severe Pulmonary Hypertension with NYHA functional classes i or ii symptoms 
who are not candidates for PMBV or Mitral Valve Repair (class iia). Both mechanical 
and biologic prostheses are used for MVR; the choice of valve often depends on 
factors such as age, need for Concomitant Anticoagulation, and Left Ventricular (LV) 
size. Morbidity and mortality are higher with prosthetic valve replacement than with 
surgical or balloon valvotomy.  
 
Definition and Causes 
Mitral Regurgitation (MR) is leakage of blood from the left ventricle into the left 
atrium during systole. It is caused by various mechanisms related to structural or 
functional abnormalities of the mitral apparatus, adjacent myocardium, or both. The 
most common causes of mitral regurgitation are rheumatic heart disease, myxomatous 
degeneration, chordal rupture, infective endocarditis, coronary artery disease, and 
cardiomyopathy . 
 
Pathophysiology and Natural History 
Significant MR leads to volume overload of the left ventricle, because it has to 
accommodate both the stroke volume and regurgitant volume with each heartbeat. To 
compensate, the left ventricle dilates and becomes hyperdynamic. In acute severe MR, 
the left atrial and pulmonary venous pressures increase quickly, leading to pulmonary 
congestion and Pulmonary Edema. In chronic MR, a gradual increase in left atrial size 
and compliance compensate so that left atrial and pulmonary venous pressures do not 
increase until late in the course of the disease. Progressive left ventricular dilation 
eventually leads to an increase in afterload, contractile dysfunction, and heart failure. 
Left atrial enlargement predisposes the patient to Atrial Fibrillation and Arterial 
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Thromboembolism. In long-standing MR, patients may develop Pulmonary  
Hypertension and right-sided heart failure. 
 
Signs and Symptoms 
Patients with chronic, severe mitral regurgitation may remain asymptomatic for years 
because the regurgitant volume load is well tolerated as a result of compensatory 
ventricular and atrial dilation. When symptoms do develop, the most common are 
dyspnea, fatigue, orthopnea, paroxysmal nocturnal dyspnea, and palpitations caused 
by Atrial Fibrillation. Acute severe MR, as occurs with chordal rupture or papillary 
muscle rupture, is almost always symptomatic because the sudden regurgitant volume 
load in the nondilated left ventricle and atrium leads to Pulmonary venous 
hypertension and congestion. 
 
The characteristic finding in a patient with MR is a blowing holosystolic murmur 
heard best at the cardiac apex. When ventricular enlargement is present, the apical 
impulse may be diffuse and laterally displaced, and a third heart sound may be heard. 
 
Diagnosis 
The chest radiograph demonstrates left atrial enlargement and cardiomegaly. Two-
dimensional and Doppler echocardiography is indicated for all patients with suspected 
mitral regurgitation to confirm its presence and determine its severity (Class I). Two-
dimensional echocardiography usually reveals the cause (e.g., the presence of 
myxomatous mitral valve disease and leaflet prolapse or evidence of underlying 
dilated cardiomyopathy). Evaluation of the severity of Mitral Regurgitation on 
echocardiography requires an integrated assessment of several parameters, including 
regurgitant jet size by Color Doppler, Regurgitant Jet Density by continuous-wave 
(CW) Doppler, and Pulmonary vein and Mitral Valve inflow by pulse-wave (PW) 
Doppler. Newer applications of Doppler echocardiography allow quantitative 
measurement of mitral regurgitation, including the regurgitant volume and the 
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regurgitant orifice area (ROA)—that is, the area through which the valve leaks in 
systole. In asymptomatic patients with significant mitral regurgitation, serial 
echocardiography every 6 to 12 months to assess LV size and systolic function is 
important for optimal timing of surgery (Class I). Transesophageal echocardiography 
is indicated for patients who are not adequately imaged by transthoracic 
echocardiography and before surgery to assess feasibility for repair (Class I). Stress 
echocardiography may be useful to assess exercise tolerance and the response of 
mitral regurgitation severity, Pulmonary pressure, and contractile reserve to exercise 
in asymptomatic patients with significant MR (Class IIa).  
 
Cardiac catheterization is no longer routinely performed to evaluate mitral 
regurgitation severity, but it is indicated for those patients in whom noninvasive test 
results are inconclusive, and also to detect concomitant Coronary Artery Disease 
(CAD) in patients undergoing mitral valve surgery (Class I).  
 
Treatment 
Medical Treatment  
In patients with acute severe MR, afterload reduction with intravenous nitroprusside 
and nitroglycerin reduces the regurgitant fraction and Pulmonary pressures. Placement 
of an intra-aortic balloon pump also helps stabilize these patients. However, these are 
temporary measures before urgent mitral valve repair or replacement. In patients with 
chronic asymptomatic Mitral Regurgitation caused by primary valve disease, there is 
no evidence for the routine use of medication in delaying the need for surgery or 
preventing left ventricular dysfunction. The management of these patients is focused 
on deciding on the appropriate timing of surgery, before the development of 
irreversible left Ventricular Dysfunction. Patients should be followed up every 6 to 12 
months to assess for symptoms and to measure left ventricular size, function, and 
severity of MR by echocardiography (Class I).  
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In patients with ischemic heart disease or dilated cardiomyopathy, mitral regurgitation 
indicates a poor prognosis. MR in these patients is called functional mitral 
regurgitation and is caused by global or regional changes in left ventricular geometry 
as well as annular dilation. Functional MR is primarily treated medically with 
antihypertensive therapy, Angiotensin Converting Enzyme (ACE) inhibitors, beta 
blockers, diuretics, and antianginal therapies when mitral regurgitation is worsened by 
acute ischemia. Biventricular Pacing has also been shown to decrease the degree of 
mitral regurgitation in dilated cardiomyopathy.  
Routine antibiotic prophylaxis for endocarditis is no longer recommended for patients 
with mitral regurgitation.  
 
Surgery  
Surgery is indicated for (1) symptomatic patients with severe primary MR (Class I) 
and (2) asymptomatic patients with severe primary MR and evidence of LV 
dysfunction (Class I). Optimal timing of mitral valve surgery is challenging in 
asymptomatic patients because the actual contractile function of the left ventricle is 
difficult to measure. The standard indications for surgery in asymptomatic patients are 
an LV end-systolic dimension of more than 4.0 cm and a resting LV ejection fraction 
of less than 60% (Class I). Other indications in asymptomatic patients include 
Pulmonary Hypertension or development of Atrial Fibrillation (Class IIa). In addition, 
mitral valve repair may be undertaken in experienced surgical centers for 
asymptomatic patients with severe MR, but without evidence of LV dilation or 
dysfunction, for which the likelihood of a successful repair is greater than 90% (Class 
IIa). Most asymptomatic patients with severe MR develop symptoms, LV dysfunction, 
or both over long-term follow-up. One retrospective study showed an increased risk of 
cardiac death (4%/year) in patients with severe mitral regurgitation based on an ROA 
of more than 0.4 cm2. However, another recent prospective study has shown that 
careful follow-up of patients with severe MR and timing of surgery based on 
symptoms, LV dysfunction, development of Atrial Fibrillation, or Pulmonary  
Hypertension is associated with an excellent patient outcome.  
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In patients with severe functional mitral regurgitation, surgery may be considered for 
severe symptoms despite medical therapy. Patients with ischemic MR may improve 
with coronary bypass surgery if significant ischemia or myocardial viability is present. 
In many coronary bypass patients with MR, concomitant mitral valve repair with an 
undersized annuloplasty ring is performed. Patients with severe left ventricular 
dysfunction and significant MR were once believed to be poor surgical candidates, but 
recent studies have shown an acceptable operative risk. Symptoms usually improve, 
although a survival benefit has not been demonstrated. 
 
The two available surgical options are mitral valve repair and mitral valve 
replacement. Mitral valve repair is the procedure of choice in the surgical 
management of MR caused by degenerative valve disease and in some cases of MR 
caused by infective endocarditis and ischemic heart disease. Repair offers several 
advantages over replacement, including lower operative time and long-term mortality, 
better preservation of LV function, a lower risk of subsequent infective endocarditis, 
and no need for long-term anticoagulation. Reoperation rates for mitral valve repair 
and replacement are similar, occurring at a rate of 1% to 2% per year. On the other 
hand, repair is technically more difficult than replacement, and many cases of mitral 
regurgitation are not amenable to valve repair. Percutaneous mitral valve repair is 
currently being investigated. The techniques involved include a clip that joins the 
mitral leaflets at their midpoint and an annuloplasty ring delivered via the coronary 
sinus.. 
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AIMS AND OBJECTIVES 
 
• A Prospective study to analyze preoperative and postoperative Pulmonary 
Hypertension following mitral valvular heart disease using preoperative 
echocardiogram, intraoperative pressure studies and postoperative 
echocardiogram. 
 
• To analyze the reduction in Pulmonary Hypertension following mitral valve 
replacement during patient follow up post surgically. 
 
• To study the effect of pharmacological agents in reduction of Pulmonary 
Hypertension preoperatively and postoperatively in mitral valvular heart 
disease. 
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Materials & Methods 
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MATERIALS AND METHODS 
A total of 265 patients were taken in this prospective study who came to the hospital 
with NYHA Class II-IV symptoms and with Mitral valvular heart lesions comprising 
of Mitral stenosis and Mitral Regurgitation with Pulmonary Hypertension from period 
of July 2007 –July 2009. 
 
A detailed clinical examination and investigations were done on these patients and 
were categorized according to the study. All patients were prepared and consented 
before surgery as per the protocol and were operated under same conditions. All of 
them underwent Mitral valve replacement using St Jude’s medical valve using 
cardiopulmonary   bypass support. 
 
A detailed clinical findings and preoperative values of these 265 patients are recorded 
over a structured proforma (Annexure) for all the patients. 
 
All the patients are classified according to their age, sex, diagnosis, preoperative, 
intraoperative and post operative echo findings and result after surgery. The results 
thus obtained are tabulated and statistically analyzed and conclusions drawn 
thereafter. 
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Observations & Results 
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OBSERVATIONS AND RESULTS 
265 Patients with mitral valvular heart disease and Pulmonary Hypertension who were 
admitted in government general hospital during July 2007-july 2010 were classified 
into different groups and tabulated according to different variables as follows: 
 
AGE GROUP Vs PULMONARY  HT SEVERITY PRE OPERATIVE 
  
 
 
Severity Levels 
1- Severe 2-Non-Severe  
1 2 Total 
AGE GROUP 
 
 
 
 
 
 
 
 
 
 
 
1 
 
(10-
19)    
Count 26 10 36 
% within PULMONARY 
HT SEVERITY PRE OP 
13.3% 14.3% 13.6% 
% of Total 9.8% 3.8% 13.6% 
2 
 
(20-
29) 
Count 48 16 64 
% within PULMONARY 
HT SEVERITY PRE OP 
24.6% 22.9% 24.2% 
% of Total 18.1% 6.0% 24.2% 
3 
(30-
39) 
Count 61 18 79 
% within PULMONARY 
HT SEVERITY PRE OP 
31.3% 25.7% 29.8% 
% of Total 23.0% 6.8% 29.8% 
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Cont.. 
 
 
Severity Levels 
1- Severe 2-Non-Severe  
1 2 Total 
 4 
 
(40-
49) 
Count 50 22 72 
% within PULMONARY 
HT SEVERITY PRE OP 
25.6% 31.4% 27.2% 
% of Total 18.9% 8.3% 27.2% 
5 
 
(>50) 
Count 10 4 14 
% within PULMONARY 
HT SEVERITY PRE OP 
5.1% 5.7% 5.3% 
% of Total 3.8% 1.5% 5.3% 
 Total Count 195 70 265 
% within PULMONARY 
HT SEVERITY PRE OP 
100.0% 100.0% 100.0% 
 
Out of 265 patients analyzed 195 (73.58%) had severe Pulmonary Hypertension and 
remaining 70 patients (26.42 %) had moderate to mild Hypertension. Out of 265 
patients, age group which had affected maximum with PHT was found to be in the 3rd 
to 4th decade which is about 31.3% which is a significant productive group. Next 
group to be affected by this severe PHT was found to be in the 4th to 5th decade (18.9 
%).Age group which had affected the least was found in the 5th decade and beyond.  
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Chi-Square Tests 
 
Value df 
Asymmetrical. Sig. (2-
sided) 
Pearson Chi-Square 1.304a 4 .861 
On performing the chi-square test there was no significant 
correlation between the age group and severe Pulmonary 
Hypertension. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  134
 
 
1)  10-19 Yrs 
2)  20-29 Yrs 
3)  30-39 Yrs 
4)  40-49 Yrs 
5)  >50 Yrs 
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SEX DISTRIBUTION 
 
SEX Vs PULMONARY  HT 
SEVERITY PRE OPERATIVE 
 
 
Severity Levels 
1- Severe 2-Non-Severe 
 1 2 Total 
SEX 1 
(Female )   
Count 111 34 145 
  % within 
PULMONARY  
HT SEVERITY 
PRE OP 
56.9% 48.6% 54.7% 
% of Total 41.9% 12.8% 54.7% 
2 
 
(Male) 
Count 84 36 120 
% within 
PULMONARY  
HT SEVERITY 
PRE OP 
43.1% 51.4% 45.3% 
% of Total 31.7% 13.6% 45.3% 
Total Count 195 70 265 
% within 
PULMONARY  
HT SEVERITY 
PRE OP 
100.0% 100.0% 100.0% 
% of Total 73.6% 26.4% 100.0% 
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According to this study the female patients were affected more with severe Pulmonary 
Hypertension which constitutes about (41.9%)   and male patients constituted about 
31.7% out of the 195 patients who had severe Pulmonary Hypertension. On an 
average about 73.6% of patients had severe Pulmonary Hypertension taking both 
males and females into consideration. The distribution for mild to moderate disease 
was found to be equal. 
Statistical Method 
Value df 
Asymmetric 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 1.450a 1 .229   
 
On performing the chi-square test there was no significant statistical correlation 
between sex and Pulmonary  Hypertension.  
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1) MALE            2) FEMALE 
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MORTALITY AND PULMONARY HYPERTENSION 
PULMONARY  HT SEVERITY PRE 
OPERATIVE 
Severity Levels 
1- Severe 2-Non-Severe 
1 2 Total 
MORTALITY 0 Count 181 70 251 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
92.8% 100.0% 94.7% 
% of Total 68.3% 26.4% 94.7% 
1 Count 14 0 14 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
7.2% .0% 5.3% 
% of Total 5.3% .0% 5.3% 
 Total Count 195 70 265 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
100.0% 100.0% 100.0% 
% of Total 73.6% 26.4% 100.0% 
 
On analyzing mortality in relation to Pulmonary  Hypertension there were 14 deaths 
(5.3%) out of total number of 265 patients and which includes about 7.2% of 195 
patients known to have severe Pulmonary  Hypertension. About 94.7% patients had 
good postoperative outcome following this surgery done for severe PHT associated 
with Rheumatic Mitral valve disease. 
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Statistical Method 
Value df 
Asymmetric. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 5.306a 1 .021   
On performing the chi-square test there was a significant correlation between severe 
Pulmonary Hypertension and mortality which is a well known factor and this study 
also confirms the hypothesis. 
 
 1- No Mortality 
2-Mortality 
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PATIENTS IN NYHA POST MVR (NYHA Vs PULMONARY  HT SEVERITY 
PRE OPERATIVE) 
PULMONARY  HT SEVERITY PRE 
OPERATIVE 
Severity Levels 
1- Severe 2-Non-Severe 
1 2 Total 
NYHA 1 Count 6 48 54 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
3.3% 68.6% 21.5% 
% of Total 2.4% 19.1% 21.5% 
2 Count 172 22 194 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
95.0% 31.4% 77.3% 
% of Total 68.5% 8.8% 77.3% 
3 Count 3 0 3 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
1.7% .0% 1.2% 
% of Total 1.2% .0% 1.2% 
 Total Count 181 70 251 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
100.0% 100.0% 100.0% 
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PULMONARY  HT SEVERITY PRE 
OPERATIVE 
Severity Levels 
1- Severe 2-Non-Severe 
1 2 Total 
NYHA 1 Count 6 48 54 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
3.3% 68.6% 21.5% 
% of Total 2.4% 19.1% 21.5% 
2 Count 172 22 194 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
95.0% 31.4% 77.3% 
% of Total 68.5% 8.8% 77.3% 
3 Count 3 0 3 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
1.7% .0% 1.2% 
% of Total 1.2% .0% 1.2% 
 Total Count 181 70 251 
% within 
PULMONARY  HT 
SEVERITY PRE OP 
100.0% 100.0% 100.0% 
% of Total 72.1% 27.9% 100.0% 
About 77.3% of patients were in NYHA classification II following this surgery and 
about 21.5% were in NYHA class I followed by 1.2% in NYHA Class III. 
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REDUCTION OF PULMONARY HYPERTENSION 
T-Test 
Group Statistics 
 
SEX N Mean 
Std. 
Deviation 
Std. Error 
Mean 
PRE-OPERATIVE 
PULMONARY  HT 
1 145 72.15 19.993 1.660 
2 120 69.34 20.756 1.895 
0-MONTHS 
PULMONRY HT 
1 145 45.50 11.775 .978 
2 120 46.77 10.744 .981 
3-MONTHS 
PULMONARY  HT 
1 134 37.56 6.245 .539 
2 117 39.58 8.237 .762 
6-MONTHS 
PULMONARY  HT 
1 134 29.78 5.356 .463 
2 117 30.97 6.515 .602 
 
On analyzing the data the Pulmonary Hypertension was reduced to a mean of 
approximately 46.14mmHG immediately following surgery and significant reduction 
of about 30.38 mmHG after 6 months of surgery. At 3 months follow up the average 
reduction in PHT was about 38.57mmHG .This analysis showed that the reduction in 
PHT had a gradual course after an initial reduction from a mean PHT value of 70.75 
mmHG preoperative values. This gives us a clue that the reduction in Pulmonary 
Hypertension is a gradual one and needed change in organic level as well as in the 
dynamic level which takes some time to achieve.  
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Independent Samples Test 
 t-test for Equality of Means 
df 
Sig.(2-
tailed) 
Mean 
Difference 
PRE OP 
PULMONARY  HT 
Equal variances 
assumed 
263 .264 2.810 
Equal variances not 
assumed 
250.067 .266 2.810 
0-MONTHS 
PULMONRY HT 
Equal variances 
assumed 
263 .364 -1.270 
Equal variances not 
assumed 
260.472 .360 -1.270 
3-MONTHS 
PULMONARY  HT 
Equal variances 
assumed 
249 .028 -2.021 
Equal variances not 
assumed 
214.527 .031 -2.021 
6-MONTHS 
PULMONARY  HT 
Equal variances 
assumed 
249 .111 -1.198 
Equal variances not 
assumed 
224.980 .116 -1.198 
 
On performing the T-test on the given statistics there was a statistical significance in 
patients who had a reduction in Pulmonary Hypertension after 3 months 
postoperatively from the preoperative value. 
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Preoperative Hemodynamic in Patients with Pulmonary Hypertension 
Variable Severe PHT 
Systolic PAP (mm Hg) [range] 84.5 [75–105] 
 
Mean PAP (mm Hg) [range] 70.88 [51–90] 
 
An average systolic pressure of 84.5mmHg and a mean PAP of 70.88 mmHg were 
found in this study. 
 
INTRAOPERATIVE PHT  
S.NO MALE FEMALE 
PAP (MEAN) 62.8mmHg 73.6 mmHg 
 
An average mean PAP of 62.8mmHg and 73.6mmHg were observed in male and 
female patients respectively with severe Pulmonary Hypertension intraoperatively. 
 
POST MVR PHT (6 MONTHS) 
S.NO MALE FEMALE 
MEAN PAP 30.97mmHg  29.78mmHg 
 
An average 30.97 mmg and 29.78mmHg were recorded as mean PAP in male and 
female patients respectively following Mitral valve replacement after an observation 
of 6 months. 
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PAP AT DAY 0 
S.NO MALE FEMALE 
MEAN PAP 46.77mmHg 45.5mmHg 
At day zero the average reduction in PAP were found to be about 46.77mmHg and 
45.5mmHg in both male and female patients respectively following MVR. This is 
found to be significant observation as the immediate drastic reduction in PHT as we 
expect following valve replacement does not occur as anticipated and gives us obvious 
clues as to the reasons behind the reduction in Pulmonary  arterial pressures. 
IMMEDIATE POSTOPERATIVE DEATH 
S.NO MALE FEMALE 
DEATH 04 10 
An average of 7.07 %% of death in this study showed death in the immediate 
postoperative period which includes day 0 and day 1in patients with severe Pulmonary  
Hypertension . 
 
MEAN ACC TIME AND CPB TIME 
S.NO ACC CPB 
LEFT ATRIAL 
APPROACH 
56.6MINS 84 .56 MINS 
SEPTAL APPROACH 68.2 MINS 100.68MINS 
 
This table shows the average Aortic Cross Clamp time and Cardiopulmonary Bypass 
Time needed for the procedure. It is evident from the table that the septal approach 
takes a longer ACC and CPB time on comparison. 
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In all the 265 patients who underwent MVR, 195 of them had severe Pulmonary 
Hypertension. All of them had the classical left atrial approach through Sondergaard’s 
groove incision except 11 cases which was approached through the septum after 
opening the right atrium. 
All cases were opened through the standard median sternotomy and were done using 
cardiopulmonary bypass utilizing cardioplegic arrest to open the chamber (s). 
In about 195 out of 265 patients (73.58%), MVR was done with either partial are 
complete chordal preservation. All the patients had St Jude’s valve placed as the 
mechanical prosthetic valve. Except for the 14 deaths which occurred due to low 
cardiac output failures all other cases were weaned of the ventilator by day 1 and from 
the inotropic supports by day 2 or day 3. 
 
Those patients who had severe Pulmonary  Hypertension who underwent MVR were 
followed up using echo at day 0 ,3 months and 6 months later and results thus 
obtained showed an early reduction in about  21.16% of males and 27.35% of females 
.About 79.84% of male patients and 72.65% of female patients showed a  trend of 
reduction in Pulmonary  Hypertension in about 3- 6 months time as compared to those 
patients who showed  an immediate reduction in Pulmonary  Hypertension following 
mitral valve replacement for mitral valvular heart disease with severe Pulmonary  
Hypertension . 
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DISCUSSION 
 Pulmonary Hypertension (PH or PHT) is an increase in blood pressure in the 
Pulmonary artery, Pulmonary vein, or Pulmonary capillaries, together known as the 
lung vasculature, leading to shortness of breath, dizziness, fainting, and other 
symptoms, all of which are exacerbated by exertion. Pulmonary Hypertension can be a 
severe disease with a markedly decreased exercise tolerance and heart failure. It was 
first identified by Dr. Ernst von Romberg in 1891. According to the most recent 
classification, it can be one of five different types: arterial, venous, hypoxic, 
thromboembolic or miscellaneous 
 
SIGNS AND SYMPTOMS 
Because symptoms may develop very gradually, patients may delay seeing a physician 
for years. Common symptoms are shortness of breath, fatigue, non-productive cough, 
angina pectoris, fainting or syncope, peripheral edema (swelling around the ankles and 
feet), and rarely hemoptysis (coughing up blood). 
Pulmonary venous hypertension typically presents with shortness of breath while 
lying flat or sleeping (orthopnea or paroxysmal nocturnal dyspnea), while Pulmonary 
arterial hypertension (PAH) typically does not. 
 
DIAGNOSIS 
 A physical examination is performed to look for typical signs of Pulmonary 
Hypertension, including a loud P2 (pulmonic valve closure sound), (Para) sternal 
heave, jugular venous distension, pedal edema, ascites, hepatojugular reflux, clubbing 
etc. Evidence of tricuspid insufficiency is also sought and, if present, is consistent 
with the presence of Pulmonary Hypertension. 
Investigations include apart from the blood routine, an ECG, Echocardiogram to 
confirm diagnosis and quantify the severity, x-ray chest which shows the classical 
picture of dilated and prominent Pulmonary arteries with obliterated left cardiac 
shadow with straightening of left cardiac border. Arterial blood gas analysis or simple 
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bedside 02 saturation may give us the clue for the diagnosis. Biopsy of the lung is 
usually not indicated unless the Pulmonary Hypertension is thought to be due to an 
underlying interstitial lung disease. But lung biopsies are fraught with risks of 
bleeding due to the high intrapulmonary blood pressure. Blood BNP level is also 
being used now to follow progress of patients with Pulmonary Hypertension.  
 
Cardiac catheterization is not routinely done nowadays to quantify Pulmonary 
Hypertension as newer Echocardiography studies throw us sufficient lights for the 
evidence and measurement of Pulmonary Hypertension. 
 
Normal Pulmonary arterial pressure in a person living at sea level has a mean value of 
12–16 mm Hg (1600–2100 Pa). Pulmonary Hypertension is present when mean 
Pulmonary artery pressure exceeds 25 mm Hg (3300 Pa) at rest or 30 mm Hg (4000 
Pa) with exercise. 
Mean Pulmonary artery pressure (mPAP) should not be confused with systolic 
Pulmonary artery pressure (sPAP), which is often reported on echocardiogram reports. 
A systolic pressure of 40 mm Hg typically implies a mean pressure more than 25 mm 
Hg. Roughly, mPAP = 0.61•sPAP + 2. 
Vascular resistance is a term used to define the resistance to flow that must be 
overcome to push blood through the circulatory system. The resistance offered by the 
peripheral circulation is known as the systemic vascular resistance (SVR), while the 
resistance offered by the vasculature of the lungs is known as the Pulmonary vascular 
resistance (PVR).  
Units for measuring vascular resistance are dynes·s·cm-5 or Pascal seconds per cubic 
meter (Pa.s/m³). Pediatric cardiologists use hybrid reference units (HRU), also known 
as Wood units, as they were introduced by Dr. Paul Wood. To convert from 
dynes·s·cm-5 to Wood units you must divide by 80.  
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Normal Values For Vascular Resistance 
Systemic vascular resistance 1170 ± 270 dynes·s·cm-5 117  ± 27 MPa.s/m³
Systemic vascular resistance index 2130 ± 450 dynes·s·cm-5·m2 213  ± 45 MPa.s/m 
Pulmonary  vascular resistance 67 ± 30 dynes·s·cm-5 6.7 ±   3 MPa.s/m³ 
 
1 Calculation of resistance 
The basic tenet of calculating resistance is that flow is equal to driving pressure 
divided by resistance. 
 
CAUSES AND CLASSIFICATION 
A 1973 meeting organized by the World Health Organization was the first to attempt 
classification of Pulmonary Hypertension. A distinction was made between primary 
and secondary PH, and primary PH was divided in the "arterial plexiform", "veno-
occlusive" and "thromboembolic" forms. A second conference in 1998 at Évian-les-
Bains also addressed the causes of secondary PH (i.e. those due to other medical 
conditions), and in 2003, the 3rd World Symposium on Pulmonary  Arterial 
Hypertension was convened in Venice to modify the classification based on new 
understandings of disease mechanisms. The revised system developed by this group 
provides the current framework for understanding Pulmonary Hypertension. The 
system includes several improvements over the former 1998 Evian Classification 
system. Risk factor descriptions were updated, and the classification of congenital 
systemic-to Pulmonary shunts was revised. A new classification of genetic factors in 
PH was recommended, but not implemented because available data were judged to be 
inadequate. 
The Venice 2003 Revised Classification system can be summarized as follows:  
WHO Group I - Pulmonary arterial hypertension (PAH)  
Idiopathic (IPAH)  
  151
Familial (FPAH)  
 
Associated with other diseases (APAH): collagen vascular disease (e.g. scleroderma), 
congenital shunts between the systemic and Pulmonary circulation, portal 
hypertension, HIV infection, drugs, toxins, or other diseases or disorders  
Associated with venous or capillary disease  
WHO Group II - Pulmonary Hypertension associated with left heart disease  
Atrial or ventricular disease  
Valvular disease (e.g. mitral stenosis)  
WHO Group III - Pulmonary Hypertension associated with lung diseases and/or 
hypoxemia  
Chronic obstructive Pulmonary Disease (COPD), Interstitial Lung Disease (ILD)  
Sleep-disordered breathing, alveolar hypoventilation  
Chronic exposure to high altitude  
Developmental lung abnormalities  
WHO Group IV - Pulmonary Hypertension due to chronic thrombotic and/or embolic 
disease  
Pulmonary Embolism in the proximal or distal Pulmonary Arteries  
Embolization of other matter, such as tumor cells or parasites  
WHO Group V - Miscellaneous  
PATHOGENESIS 
Whatever the initial cause, Pulmonary arterial hypertension (WHO Group I) involves 
the vasoconstriction or tightening of blood vessels connected to and within the lungs. 
This makes it harder for the heart to pump blood through the lungs, much as it is 
harder to make water flow through a narrow pipe as opposed to a wide one. Over time, 
the affected blood vessels become both stiffer and thicker, in a process known as 
  152
fibrosis. This further increases the blood pressure within the lungs and impairs their 
blood flow. In addition, the increased workload of the heart causes thickening and 
enlargement of the right ventricle, making the heart less able to pump blood through 
the lungs, causing right heart failure. As the blood flowing through the lungs 
decreases, the left side of the heart receives less blood. This blood may also carry less 
oxygen than normal. Therefore it becomes harder and harder for the left side of the 
heart to pump to supply sufficient oxygen to the rest of the body, especially during 
physical activity. 
Pathogenesis in Pulmonary venous hypertension (WHO Group II) is completely 
different. There is no obstruction to blood flow in the lungs. Instead, the left heart fails 
to pumps blood efficiently, leading to pooling of blood in the lungs. This causes 
Pulmonary edema and pleural effusions. 
In hypoxic Pulmonary Hypertension (WHO Group III), the low levels of oxygen are 
thought to cause vasoconstriction or tightening of Pulmonary arteries. This leads to a 
similar pathophysiology as Pulmonary  arterial hypertension. 
In chronic thromboembolic Pulmonary Hypertension (WHO Group IV), the blood 
vessels are blocked or narrowed with blood clots. Again, this leads to a similar 
pathophysiology as Pulmonary arterial hypertension. 
 
TREATMENT 
Treatment is determined by whether the PH is arterial, venous, hypoxic, 
thromboembolic, or miscellaneous. Since Pulmonary venous hypertension is 
synonymous with congestive heart failure, the treatment is to optimize left ventricular 
function by the use of diuretics, beta blockers, ACE inhibitors, etc., or to 
repair/replace the mitral valve or aortic valve. 
In PAH, lifestyle changes, digoxin, diuretics, oral anticoagulants, and oxygen therapy 
are considered conventional therapy, but have never been proven to be beneficial in a 
randomized, prospective manner. 
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A number of agents has recently been introduced for primary and secondary PAH. 
The trials supporting the use of these agents have been relatively small, and the only 
measure consistently used to compare their effectivity is the "6 minute walking test". 
Many have no data on mortality benefit or time to progression.  
  
VASOACTIVE SUBSTANCES 
Many pathways are involved in the abnormal proliferation and contraction of the 
smooth muscle cells of the Pulmonary arteries in patients with Pulmonary arterial 
hypertension. Three of these pathways are important since they have been targeted 
with drugs — endothelin receptor antagonists, phosphodiesterase type 5 inhibitors15, 
and prostacyclin derivatives. 
 
Because inexpensive generic drugs for this disease are not widely available, the World 
Health Organization does not include them in its model list of essential medicines. 
 
 PROSTAGLANDINS 
Prostacyclin (prostaglandin I2) is commonly considered the most effective treatment 
for PAH. Epoprostenol (synthetic prostacyclin, marketed as Flolan) is given via 
continuous infusion that requires a semi-permanent central venous catheter. This 
delivery system can cause sepsis and thrombosis. Flolan is unstable, and therefore has 
to be kept on ice during administration. Since it has a half-life of 3 to 5 minutes, the 
infusion has to be continuous (24/7), and interruption can be fatal. Other prostanoids 
have therefore been developed. Treprostinil (Remodulin) can be given intravenously 
or subcutaneously, but the subcutaneous form can be very painful. An increased risk 
of sepsis with intravenous Remodulin has been reported by the CDC. Iloprost 
(Ilomedin) is also used in Europe intravenously and has a longer half life. Iloprost 
(marketed as Ventavis) is the only inhaled form of prostacyclin approved for use in 
the US and Europe. This form of administration has the advantage of selective 
deposition in the lungs with less systemic side effects. Oral and inhaled forms of 
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Remodulin are under development. Beraprost is an oral prostanoid available in Japan 
and South Korea. ENDOTHELIN RECEPTOR ANTAGONISTS 
The dual (ETA and ETB) endothelin receptor antagonist bosentan (marketed as 
Tracleer) was approved in 2001. Sitaxentan, a selective endothelin receptor antagonist 
that blocks only the action of ETA, has been approved for use in Canada, Australia, 
and the European Union, to be marketed under the name Thelin. Sitaxentan has not 
been approved for marketing by the U.S. Food and Drug Administration (FDA). A 
new trial to address the FDA's concerns had begun in 2008. A similar drug, 
ambrisentan is marketed as Letairis in U.S. In addition, another dual/nonselective 
endothelin antagonist, Actelion-1, from the makers of Tracleer, had entered  clinical 
trials in 2008. 
 
PHOSPHODIESTERASE TYPE 5 INHIBITORS 
Sildenafil, a selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5), 
was approved for the treatment of PAH in 2005. It is marketed for PAH as Revatio. 
We had used this medication in about 73 (195) of the patients with severe Pulmonary 
Hypertension in our study. 
ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE 
 
Soluble guanylate cyclase (sGC) is the intracellular receptor for NO. As of April 
2009, the sGC activators cinaciguat and riociguat are undergoing clinical trials for the 
treatment of PAH  
 
Treatment for hypoxic and miscellaneous varieties of Pulmonary Hypertension has not 
been established. However, studies of several agents are currently enrolling patients. 
Many physicians will treat these diseases with the same medications as for PAH, until 
better options become available. Such treatment is called off-label. 
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MONITORING 
Patients are normally monitored through commonly available tests such as: 
¾ Pulse oximetry,  
¾ Arterial blood gas tests,  
¾ Chest X-rays,  
¾ Serial ECG tests,  
¾ Serial echocardiography. 
 
 
In all our 265 patients who underwent MVR 195 had severe Pulmonary Hypertension 
and females 111/195(56.9%) outnumbered the males in this diagnosis. The immediate 
reduction of Pulmonary Hypertension happened in only approximately 21 % of the 
patients and the remaining had persistent PHT which showed a fall progressively 
following a 6 months period suggesting the various factors which might be 
responsible for the Pulmonary Hypertension. 
 
The average mortality noted in this study was comparatively less (7.2%) % than an 
expected value of about 10-15% by the previous studies. The difference might be 
because of the earlier decision to operate upon this severe group before irreversible 
factors sets in and also due to the better intraoperative and postoperative care using 
latest agents so far approved for this purpose. 
 
However the long-term follow up of these patients are needed to conclude firmly 
regarding the use of newer agents used to reduce Pulmonary  Hypertension either 
intraoperatively are postoperatively. 
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17 patients among the total patients required a septal approach due to the concomitant 
presence of tricuspid regurgitation and hence the need for devega procedure done for 
them. 
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CHEST X-RAY OF SEVERE PULMONARY HYPERTENSION
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C 
 
ECHO  DOPPLER PICTURE OF SEVERE PULMONARY HYPERTENSION
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                     EXCISED SPECIMEN OF MITRAL VALVE 
 
 
                     
          DOPPLER IMAGE OF RHEUMATIC MITRAL STENOSIS 
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PRE-CARDIOPULMONARY BYPASS PICTURESHOWING DILATED MAIN  
                                      PULMONARY ARTERY                      
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INTRAOPERATIVE PULMONARY PRESSURE MEASUREMENT  
USING NEEDLE 
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INTRAOPERATIVE PULMONARY PRESSURE RECORDING
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PHOTOGRAPH SHOWING RHEUMATIC MITRAL VALVE EXPOSURE ON 
                                 CARDIOPULMONARY BYPASS
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INTRAOPERATIVE PICTURE SHOWING INSERTION OF St JUDE’S 
       MECHANICAL PROSTHETIC VALVE IN MITRAL POSITION 
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Summary & Conclusion 
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SUMMARY &CONCLUSION 
Pulmonary arterial hypertension has long been considered a risk factor for poor 
outcome in patients undergoing MVR, with operative mortality ranging from 15%–
31%. Najafi and colleagues found the degree of PAH correlated strongly with 
perioperative mortality, ranging from 16% in patients with mild PAH to 23% in severe 
PAH and 61% when PAP was at systemic levels. Recently, several reports have 
demonstrated improved outcome in patients with PAH undergoing MVR, with 
perioperative mortality ranging from 2.3%–10%.The improved outcome was 
attributed to better myocardial preservation, preservation of the subvalvular apparatus, 
and improved postoperative care. In our study, the overall operative mortality rate was 
7.07 % which is consistent with recent reports. However, the mortality rate in patients 
with PHT overall was 5.5 % which is better than the recent reports.  
Numerous studies have examined hemodynamic changes in this subset of patients at 
different intervals after mitral valve procedures. Most have demonstrated an 
immediate reduction in PAP and PVR, signifying a sudden drop in left atrial pressure 
and reversal of the severe spastic Pulmonary vasoconstriction that accompanies left 
atrial hypertension in some patients. Others have shown slow regression of elevated 
PAP and PVR several months postoperatively. These reports point toward the 
involvement of multiple factors in the development of PAH in mitral valve disease. 
There have been studies of closed mitral commissurotomy and balloon mitral 
valvotomy in this subgroup of patients from India, which have shown good results in 
terms of survival, postoperative functional class, and hemodynamics. In our study the 
mean PAP and PVR did not fall significantly immediately following MVR .The mean 
fall in PAP was about 46.77 % in males and 45.5% in females which was against the 
previous views .Although the mean PAP fell significantly from 84.5 to 70.88%  mm 
Hg, it remained within the definition of severe PAH. The PVR showed no significant 
reduction immediately after MVR, but a gradual regression was seen over a 6 months 
period and the fall was significant at 6 months period when compared with the 
preoperative values. This indicates the reactive component of Pulmonary arterial 
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vasoconstriction, which may be responsible for part of the disproportionate elevation 
of PVR seen in as many as 20% of patients undergoing mitral valve procedures.  
The persistence of residual elevated PAP and PVR well beyond the normal limit in 
patients suggests an irreversible component of the increased PVR. Other variables that 
determine the immediate and long-term results of surgery in this subset of patients 
include advanced age, acute presentation, decreased left ventricular ejection fraction, 
functional class, right heart failure and increased left ventricular end-diastolic 
pressure. Vincens and colleagues identified clinical right heart failure as a predictor of 
operative mortality, and both right ventricular systolic pressure and right ventricular 
hypertrophy as predictors of poor outcome. Others have identified severe tricuspid 
regurgitation and the need for concomitant tricuspid surgery as risk factors for 
operative mortality in this population. In this study, 47% of patients had right 
ventricular hypertrophy and/or dilatation, and 33% had severe tricuspid regurgitation.  
Despite the high operative mortality in most series of MVR in patients with severe 
PAH, a striking improvement in survival was noted. In our series, functional class 
improved by one class or more in the majority of survivors. Long-term morbidity was 
related mainly to anticoagulation and was attributed to poor patient compliance due to 
illiteracy in this part of the world. Repair of the mitral valve in patients with 
predominant MR could have avoided these complications but it was not undertaken 
because of the high rate of repair failure in patients with rheumatic etiology of mitral 
regurgitation as well as severe subvalvular pathology with calcification of leaflets in 
most of them.  
I acknowledge that the lack of follow-up of Pulmonary vascular dynamics by 
catheterization constitutes a limitation of this study and was related primarily to 
economic factors. A postoperative lung biopsy might have added to the information, 
but this was not undertaken as most of the patients refused consent for it.  
 
I conclude that MVR is safe and effective even in the presence of severe PAH as long 
as the Pulmonary  arterial pressures are below systemic pressures. With supra-
systemic PAP, MVR carries a high risk of mortality, and the patient continues to have 
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persistent PAH in the postoperative period. Significant reduction in PHT following 
MVR takes place only gradually and in this study about 6 months period showed a 
decline in PHT as compared to the previous belief of immediate reduction in PHT in 
majority of the patients.  
 
This explains the multifactorial causes of PHT in patients with Rheumatic mitral 
valvular heart disease and severe Pulmonary  Hypertension. 
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PROFORMA 
 
NAME:                                           AGE:          SEX:                                      
 
OCCUPATION:                             DATE OF ADMISSION: 
 
 
 
 
ADDRESS FOR COMMUNICATION:   
 
 
ADMISSION DIAGNOSIS:   MS                  MS+MR                                    MR                       
LA CLOT 
 
 
BRIEF HISTORY              : DOE           ANGINA            PALPITATION               
PND            ORTHOPNOEA       OLIGURIA         PE       
 
 
 
NYHA CLASS         :         1                2             3           4        5 
 
 
RHEUMATIC HEART DISEASE      :               YES               NO   
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H/0 ANTIFAILURE MEDICATION:                 YES               NO 
 
 
GENERAL EXAMINATION   :   HT                WT                    HR                  BP                  
A /ICTERUS/CYANOSIS/PEDAL OEDEMA/JVP 
 
 
CVS EXAMINATION    :   RV IMPULSE               LV IMPULSE              AF   a) 
present b) absent.            
 
HEART SOUNDS          : S1 S2            S1 LOUD    VARIABLE           SOFT  
                                             S3 S4         YES           NO           
                                             P2   LOUD, SOFT 
   
 
CARDIAC MURMERS             : MDM            GRADE 
                                                        PSM             GRADE 
 
RESPIRATORY SYSTEM        : BAE                      ; ADDED SOUNDS               
a) RHONCHI    b) FINE CREPTS 
 
 
ABDOMEN                                  :   HEPATOMEGALY 
                                                           SPLENOMEGALY 
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                                                           ASCITES 
 
CNS                                              : NEUROLOGICAL DEFICIT. 
 
 
INVESTIGATIONS              : BLOOD TC          DC                  ESR                      
PCV               Hb            PL COUNT 
 
 
                                                 BT                CT 
                                         
                               BLOOD UREA                   BLOOD SUGAR                   S. 
CREATININE                  S.          Na             k 
 
                   ECG        RVH           P mitrale            LVH               AF                ST-T 
SEGMENT            OTHERS 
 
 
                                                X-RAY CHEST        :                       
CT RATIO : 
 
  BLOOD GROUPING & Rh Typing 
 
                                               ECHO:   MVO          MVA            LEAFLET             
MOBILITY                  THICKENING      Ca +         SCF 
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 LA SIZE                         PHT   a) mild   b)           moderate                       
c) severe 
 
                                                                 LV DIMENSION                                    EF: 
 
                                               
  CORONARY ANGIOGRAM: 
 
 
 
 
INTRA OP DETAILS: TOTAL CPB TIME               TOTAL 'X ' CLAMP TIME            
CP   1   2    3 4 
 
                                         VALVE SIZE    :  
                                         
 PULMONARY ARTERY PRESSURE SYSTOLE:                      DIASTOLE:            
 
 
 
 
POST OP DETAILS: PULMONARY ARTERY PRESSURE SYSTOLE:                     
DIASTOLE: 
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POSTOP       : VENTILATOR SUPPORT   :   <24 HRS   24-48 HRS                  
48-72 HRS               >72 HRS 
 
 INOTROPES   : DOP/DOB               DOP+DOB                DOP/DOB+ADR/ISO           
OTHERS 
   
 
 COMPLICATIONS               : SSSI                          STERNAL DEHISCENCE                    
LCOS            MODS 
 MORTALITY                         : LCOS                      ARRHYTHMIA                       
SUDDEN CARDIAC ARREST 
 
 
 
 
IMMEDIATE POSTOPERATIVE : PULMONARY  ARTERY PRESSURE   : 
 3 MONTHS    
    
 6 MONTHS 
                                                 
 1 YEAR. 
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MASTER CHART 
S.No NAME AGE 
AGE 
GROUP* 
DURATION    
SEX SEX** DEATH 
PREOP PHT 
(mmHg) 
0 MON 
(mmHg) 
3 MON          
(mmHg) 
6 MON 
(mmHg) 
SEVERITY   
NYHA NYHA*** 
1 GANDHIMATHY 45 4 1 1 0 80 40 35 25 1 2 
2 MD.ALI 27 2 2 2 0 70 38 32 30 1 2 
3 NASRUDEEN 47 4 1 2 0 75 48 30 26 1 2 
4 VARALAXMI 42 4 2 1 0 86 52 40 36 1 2 
5 ANNATHAI 35 3 2 1 0 78 50 44 30 1 1 
6 RAJAMNI 27 2 1 2 0 74 46 40 36 1 2 
7 RAJAMAL 29 2 2 1 0 38 30 26 20 1 1 
8 KARTHIK 25 2 1 2 0 36 30 24 20 1 1 
9 CHANDRA            40 4 2 1 0 88 48 38 30 1 2 
10 NADIYA 18 1 2 1 0 78 44 40 36 1 2 
11 BALA 30 3 3 2 0 90 54 40 36 1 2 
12 MALATHI 20 1 1 1 0 40 32 26 24 1 1 
13 RANI 50 5 2 1 0 86 46 40 30 1 2 
14 RAMAR                24 2 2 2 0 80 50 40 32 1 2 
15 LAKSHMI 45 4 2 1 0 74 46 44 30 1 2 
16 PARTHIBAN         27 2 1 2 0 40 32 30 26 1 2 
17 MARYRANI          35 3 1 1 0 36 30 28 20 1 2 
18 MANJULA 35 3 2 1 0 76 44 40 32 1 2 
19 LAKSMIDEVI        45 4 1 1 0 82 46 40 32 1 2 
20 MANI 45 4 2 2 0 78 52 46 34 1 2 
21 SEKAR 43 4 3 2 0 40 36 30 22 1 2 
22 NAGARAJ            48 4 2 2 1 94 88     0   
23 RADHABAI           49 4 1 1 0 76 48 44 34 1 2 
 
24  MANIKANDAN        16 1 3 2 0 40 36 30  28  1  2
25  BALASUBRAMANI              2 27 2 2 2 0 80 56 52  34  1  2
26  RENUKA  20 2 2 1 0 36 30 28  20  1  1
27  SANTHOSH           19 1 2 2 0 68 54 48  40  1  1
28  ELUMALAI  50 5 2 2 0 38 34 30  22  1  2
29  RAMACHANDRA    15 1 2 2 0 88 52 46  38  1  2
30  PONNAMAL           47 4 2 1 0 40 32 30  20  1  2
31  SIVAJIRAO                      4  44 4 1 2 0 78 50 46  38  1  2
32  SAROJA                            4  49 4 2 1 0 34 30 22  20  1  2
33  UMA  38 3 2 1 0 90 40 34  30  1  2
34  MEENAKSI            28 2 1 1 0 88 38 36  26  1  2
35  ANJALI                  30 3 2 1 0 90 48 40  32  1  2
36  THIIRUMATHY       15 1 2 1 0 30 28 24  20  1  2
37  UMAPATHY           45 4 2 2 0 72 56 44  36  1  2
38  INDRANI  34 3 2 1 0 70 44 30  28  1  2
39  SARAVANAN                     2 25 2 2 2 0 40 38 36  30  1  1
40  ANURADHA           32 3 2 1 0 84 44 36  30  1  2
41  MANJULA  43 4 3 1 0 90 48 40  36  1  2
42  KUMAUDHA           21 2 2 1 0 98 46 40  38  1  2
43  EZHIL                                 4  45 4 2 2 0 84 58 50  46  1  2
44  SANGEETHA                     2  22 2 2 1 0 70 40 38  30  1  2
45  KALAIVANI                         2  26 2 2 1 0 82 42 40  30  1  2
46  RAMASAMI            29 2 2 2 0 86 44 38  30  1  2
47  KUMAR                             4  40 4 2 2 0 40 36 30  24  1  2
48  KAVERI  47 4 2 1 0 90 44 38  34  1  2
49  MURUGAN             32 3 1 2 0 70 44 32  30  1  2
50  SUBRAMANI          42 4 2 2 0 78 48 40  32  1  2
51  SHANTHI  45 4 2 1 0 88 40 32  28  1  2
52  MURUGAIAN          52 5 2 2 1 80 74            
53  GOMATHY             40 4 3 1 0 36 30 28  20  1  2
54  AMARAVATHY      45 4 2 1 0 42 36 30  22  1  1
55  PRABU  21 2 1 2 0 78 50 44  32  1  2
56  VEERAMANI          36 3 2 2 0 78 44 38  26  1  3
57  KUMARAN             35 3 2 2 0 42 40 36  20  1  2
58  ANNAKILI               26 2 2 1 0 74 46 42  36  1  2
59  MANI  30 3 1 2 0 80 54 50  38  1  2
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60  NALINI  25  2  1  1  0  76  48  46  32  1  2 
61  SUBAKUTI             30  3  2  2  0  40  36  30  22  1  1 
62  MASTHAN  45  4  2  1  0  78  44  38  36  1  2 
63  JEELAN  40  4  2  2  0  36  34  30  20  1  1 
64  PETER  50  5  2  2  0  40  34  30  20  1  1 
65  SUMATHY  26  2  1  1  0  78  40  34  24  1  2 
66  SHANTHI  34 3 2 1 0 76 44 42 30 1  2 
67  HARI  45 4 2 2 0 36 30 28 20 1  1 
68  KOLA  15 1 2 1 0 72 40 38 26 1  2 
69  MANGAI  35 3 1 1 0 42 36 30 22 1  1 
70  SARASWATHY                  4  45 4 1 1 0 50 48 40 38 1  2 
71  DHANALAKSMI      53 5 2 1 0 30 28 26 20 1  1 
72  MOHAN  39 3 2 2 0 94 56 50 42 1  2 
73  SELVI  43 4 2 1 0 80 42 40 36 1  2 
74  CHANDRASEKAR               4              1  47 4    2 0 88 54 50 34 1  2 
75  NANDHINI  13 1 1 1 0 80 60 48 38 1  3 
76  AMBA  30 3 2 1 0 72 44 40 32 1  2 
77  SHANMUGAVALI              40              4 40 4    1 0 76 40 38 26 1  2 
78  KALA                                 1  18 1 2 1 0 82 40 36 22 1  2 
79  NADHIYA  18 1 2 1 0 70 46 40 32 1  2 
80  DILLIBABU                         4  48 4 2 2 0 42 32 30 24 1  1 
81  VARADHARAJ                  3  39 3 1 2 0 40 34 30 26 1  1 
82  KUMAR  27 2 2 2 0 76 52 48 36 1  2 
83  KALAVATHY          44 4 1 1 0 90 48 42 36 1  2 
84  SILAMBARASAN    27 2 2 2 0 74 52 50 40 1  2 
85  PERUMAYEE         47 4 3 1 0 40 36 30 26 1  1 
86  ALGUMANI             42 4 2 2 0 90 48 40 36 1  2 
87  SHANU  35 3 2 1 0 78 50 46 24 1  2 
88  MUNIAMMAL                42 4 2 1 0 86 48 40 36 1  2 
89  ATHIRUBAN                       3  39 3 2 2 0 78 44 40 32 1  1 
90  NATRAJAN                        2  27 2 1 2 0 30 26 20 18 1  1 
91  RAJAMMAL            45 4 2 1 0 74 40 36 30 1  1 
92  MURUGAN             18 1 2 2 0 78 40 42 32 1  2 
93  VENKATESAN        44 4 2 2 0 80 46 38 26 1  2 
94  DURAISAMI  43 4 2 2 0 40 38 36 24 1  1 
95  GOPI  16 1 1 2 0 80 46 40 38 1  2 
96  ELANGOVAN  39 3 2 2 0 74 50 44 34 1  2 
97  AYYAPAN  33 3 1 2 0 36 30 28 20 1  1 
98  SALEEMA  22 2 1 1 0 40 32 30 24 1  2 
99  ELANGOVAN  39 3 3 2 0 76 54 48 34 1  2 
100  SAHINBEGUM  46 4 2 1 0 80 48 40 34 1  2 
101  SHANTHI  21 2 2 1 0 72 40 36 30 1  2 
102  SELVI  18 1 2 1 0 68 40 38 30 1  2 
103  RAJI  33 3 2 1 0 80 48 40 32 1  2 
104  DHATCHANAMOORTHI  25 2 1 2 0 78 48 44 36 1  2 
105  PARTHASARATHI   35 3 2 2 0 36 30 28 22 1  2 
106  SEKAR  44 4 2 2 0 80 48 40 38 1  2 
107  SHAJIN  46 4 2 1 0 74 48 43 37 1  1 
108  SEKAR  44 4 1 2 0 80 58 48 38 1  2 
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109  SARVANAN  47 4 2 2 0 76 42 38 30 1  2 
110  RAJESVARI  14 1 2 1 0 40 35 28 22 1  2 
111  DEIVANI  52 5 3 1 0 80 48 47 35 1  2 
112  IYYAPAN  20 2 2 2 0 40 30 28 22 1  1 
113  ESAKKIAPPAN      40 4 1 2 0 70 48 40 36 1  2 
114  PONNAN  45 4 2 2 0 80 58 50 36 1  3 
115  LAKSMIDEVI          18 1 2 1 0 70 40 38 33 1  2 
116  SUGANTHI  35 3 2 1 0 76 44 39 27 1  2 
117  NADIYA  26 2 1 1 0 30 26 20 18 1  1 
118  MADAN  15 1 4 2 0 34 30 27 23 1  1 
119  ARUN  23 2 2 2 0 40 36 30 22 1  1 
120  LALITHA  29 2 2 1 0 78 48 40 42 1  2 
121  RANI  28 2 1 1 0 88 40 38 30 1  2 
122  SHANMUGAM  42 4 2 2 0 36 32 30 25 1  1 
123  JANAKIRAMAN  15 1 1 2 0 86 58 50 32 1  2 
124  MAHESVARI  24 2 2 1 0 88 46 40 32 1  2 
125  VATCHALA  59 5 2 1 0 86 44 42 38 1  2 
126  NANDHINI  30 3 2 1 0 38 34 30 24 1  1 
127  GOVINDAN  33 3 2 2 0 88 48 40 37 1  2 
128  MARINESAN  53 5 1 2 0 88 49 47 35 1  2 
129  VASANTHI  30 3 2 1 0 40 38 30 28 1  2 
130  PERIASAMI  49 4 2 2 0 38 32 30 25 1  1 
131  KOLANCHIAPPAN  38 3 1 2 0 90 54 47 33 1  2 
132  VIDHYA  17 1 2 1 0 44 39 27 20 1  1 
133  VASANTHI  25 2 1 1 0 32 30 27 22 1  1 
134  DILIP  23 2 2 2 0 80 49 44 38 1  2 
135  RAMADURAI  36 3 2 2 0 88 49 42 31 1  2 
136  THANGAKODI  61 2 1 1 0 40 38 34 31 1  1 
137  GEETHA  31 3 2 1 0 80 48 40 36 1  2 
138  AYYASAMI  26 2 2 2 0 80 59 47 34 1  2 
139  KESAVAN  37 3 2 2 0 88 53 45 33 1  2 
140  MURUGESAN  36 3 1 2 0 90 56 50 37 1  2 
141  THENMOZHI  38 3 2 1 0 92 46 44 33 1  2 
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142 MURUGAMMAL 20 2 2 1 0 90 56 49 37 1 2 
143 BASKAR 18 1 2 2 0 88 49 43 37 1 2 
144 MINNALKODI 35 3 2 1 0 90 48 42 36 1 2 
145 PANDURANGAN 36 3 2 2 0 40 36 30 24 1 1 
146 SIVAPRAKASH 40 4 2 2 0 32 28 20 18 1 1 
147 DEVI 23 2 1 1 0 86 46 40 38 1 2 
148 SIVAGAMI 40 4 2 1 0 40 32 30 24 1 1 
149 YASODHA 54 5 2 1 0 86 48 40 34 1 2 
150 CHINNARAJ 15 1 2 2 0 46 36 30 22 1 1 
151 SARASWATHY                  4 35 3 1 1 0 94 48 40 32 1 2 
152 RAJA 18 1 2 2 0 90 50 42 36 1 2 
153 SHANTHI 23 2 1 1 0 86 40 36 30 1 2 
154 MARIAMMAL 29 2 2 1 0 88 48 40 36 1 2 
155 SUMITHRA 27 2 1 1 0 90 48 40 36 1 2 
156 LAKSHMI 16 1 2 1 1 88           
157 GOPAL 47 4 2 2 0 40 36 30 22 1 2 
158 SASIKALA 32 3 2 1 0 36 30 28 22 1 1 
159 VIJAYALAKSHMI 14 1 2 1 0 90 46 40 32 1 2 
160 PATCHIAPPAN 38 3 2 2 0 88 58 50 40 1 2 
161 KOUSALYA 31 3 2 1 0 82 46 43 31 1 2 
162 DEVENDRAN 49 4 1 2 0 88 49 41 39 1 2 
163 KANNAN 43 4 2 2 0 70 41 37 26 1 1 
164 RAMALINGAM 40 4 1 2 0 80 47 40 32 1 2 
165 JEYASHANKAR 21 2 2 2 0 78 58 47 32 1 2 
166 GAJALAKSHMI 58 5 2 1 0 32 30 27 22 1 1 
167 RAMASAMI           40 4 1 2 0 70 55 43 31 1 2 
168 KRISNAMOORTHY 49 4 2 2 0 80 44 37 29 1 2 
169 THILLAIAMMAL 28 2 2 1 0 78 49 37 27 1 2 
170 RAJENDREN 38 3 2 2 0 40 32 20 22 1 2 
171 NANDHINI 16 1 2 1 0 86 56 47 32 1 2 
172 ROUTRAJ 32 3 2 1 0 70 46 41 28 1 2 
173 SATHYA 34 3 2 1 0 38 36 34 30 1 2 
174 JEYARAMAN 62 5 3 2 0 82 56 49 37 1 2 
175 RAMACHANDRAN 22 2 2 2 0 90 59 44 32 1 2 
176 KRISNAMOORTHY 48 4 2 2 0 40 36 32 22 1 2 
177 DHANALKSHMI 32 3 2 1 0 90 46 42 36 1 2 
178 VIMALA 42 4 2 1 1 90           
179 SAMINATHAN 40 4 1 2 0 76 54 49 32 1 2 
180 PARI 32 3 2 2 0 88 48 39 21 1 2 
181 VELAYUTHAN 35 3 2 2 0 80 46 40 36 1 2 
182 MAALIGA 34 3 2 1 1 90           
183 JEYACHANDRAN 16 1 2 2 0 80 54 49 37 1 2 
184 ADAIKALARAJ 24 2 2 2 0 88 48 45 36 1 2 
185 MARIAMMAL 17 1 2 1 0 78 46 40 34 1 2 
186 RENUKADEVI 20 2 2 1 0 80 47 39 31 1 2 
187 SATHYA 18 1 2 1 1 88           
188 RAVI 38 3 1 2 0 90 58 50 42 1 2 
189 PALANIAMMAL 37 3 2 1 0 88 48 39 27 1 2 
190 LATHA 31 3 2 1 0 80 42 40 27 1 2 
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191 SARAVANAN                     1 14 1 2 2 0 36 30 28 22 1 1 
192 BALAMANI 27 2 2 1 0 80 44 40 28 1 2 
193 INDRANI 28 2 2 1 0 88 48 36 32 1 2 
 
195 PANNERSELVAM 48 4 1 2 0 90 55 48 37 1 2
196 DHANASELVI 30 3 2 1 0 82 42 40 35 1 2
197 SUDHA 18 1 2 1 0 90 48 40 36 1 2
198 KABILAN 39 3 2 2 0 84 47 38 32 1 2
199 SHEIK 28 2 2 2 0 70 50 40 32 1 2
200 SENNAMA 40 4 3 1 0 38 32 28 22 1 1
201 JEGANNATHAN 35 3 2 2 0 90 57 46 37 1 2
202 TAMILSELVI 36 3 2 1 0 40 36 32 28 1 1
203 PARVATHAM 40 4 2 1 0 86 46 40 32 1 2
204 MUNEESHVARI 35 3 2 1 0 86 46 40 34 1 2
205 MUNUSWAMI 27 2 2 2 0 90 59 47 35 1 2
206 SAMINATHAN 40 4 2 2 0 88 56 47 34 1 2
207 SHANTHI 37 3 1 1 0 38 32 30 24 1 1
208 KOMALA 30 3 1 1 1 40           
209 MURUGESVARI 32 3 2 1 0 80 46 39 32 1 2
210 BALAJI 19 1 2 2 0 78 44 40 32 1 2
211 VENKATESAN       24 2 2 2 0 40 38 33 27 1 1
212 NABISHA 47 4 2 1 0 80 48 39 31 1 2
213 EZHILRANI 28 2 2 1 0 80 56 48 36 1 2
214 KAVITHA 30 3 2 1 0 38 30 28 20 1 1
215 KRISHNAVENI 32 3 2 1 1 90 88         
216 MUTULAXMI 35 3 2 1 1 90 80         
217 VINOTHA 22 2 2 1 1 88 80         
218 RAVIKUMAR 47 4 1 2 0 30 28 26 21 1 1
219 SOUNDARYA 28 2 2 1 0 80 48 42 32 1 2
220 ARJUNAN 16 1 2 2 0 40 36 30 26 1 2
221 DURAISAMI 42 4 2 2 0 88 50 46 31 1 2
222 MALARKODI 31 3 2 1 0 80 42 40 32 1 1
223 KARTHIK 39 3 2 2 0 90 48 36 25 1 2
224 KIRTHIHA 17 1 2 1 0 88 42 40 28 1 2
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225 SUDHA 28 2 1 1 1 90 76       
226 VENKATESAN       22 2 2 2 0 78 56 50 35 1
227 PALANI 32 3 2 2 0 40 36 30 32 1
228 PARVATHI 40 4 2 1 0 88 44 40 32 1
229 SELVAMARI 28 2 2 1 0 78 42 40 32 1
230 SUDHA 28 2 2 1 0 40 36 30 22 1
231 SHNTHAKUMARI 40 4 2 1 0 34 32 28 22 1
232 SHANMUGAM 51 5 2 2 0 88         
233 ANJALAIDEVI 26 2 2 1 0 88 50 46 32 1
234 KASTHURI 30 3 2 1 0 78 48 40 32 1
235 KANNIAPPAN 36 3 2 2 0 90 56 50 40 1
236 PALANISAMI 40 4 2 2 0 40 34 32 30 1
237 ABITHA 25 2 1 1 0 90 50 48 32 1
238 GOMATHY            30 3 2 1 0 9048 40 30 26 1
239 JADAMANI 36 3 2 2 0 80 50 44 32 1
240 CHANDRAMATHI 32 3 2 1 0 88 50 47 34 1
241 MUTHU 40 4 2 2 0 80 54 42 36 1
242 SIVAGAMAI 40 4 2 1 0 80 46 42 34 1
243 PRABHU 35 3 2 2 0 90 58 50 32 1
244 SADASIVAM 45 4 1 2 0 78 56 46 32 1
245 EDWARD 58 5 2 2 0 80 48 40 28 1
246 SUGANTHI 17 1 2 1 0 88 48 46 38 1
247 SARALA 23 2 2 1 0 90 42 38 27 1
248 RATHINAVELU 54 5 2 2 0 86 46 40 32 1
249 SARASWATHY                  4 23 2 2 1 0 78 46 40 27 1
250 PALANIAMMAL 45 4 2 1 0 70 48 40 34 1
251 SANGEETHA                    2 19 1 2 1 0 70 48 40 36 1
252 SNEHA 18 1 2 1 0 90 59 48 31 1
253 SANGEETHA                     2 20 2 2 1 0 72 48 40 28 1
254 SUMATHY 35 3 2 1 1 82         
255 SAMUNSEHVARI 15 1 1 1 0 78 48 42 28 1
256 SHANKAR 13 1 1 2 0 80 58 50 45 1
257 MAHESHVARI 35 3 2 1 1 90 80       
258 CHITRA 24 2 2 1 0 90 47 36 28 1
259 KAVITHA 25 2 2 1 0 38 36 32 30 1
260 JANAKI 33 3 2 1 0 80 50 42 34 1
261 LAKSHMI 26 2 2 1 0 40 32 30 22 1
262 MUNUSWAMI 35 3 2 2 0 90 54 48 35 1
263 AYYANAR 35 3 2 2 0 86 54 50 40 1
264 GOPALAKRISHNAN 42 4 1 2 0 86 52 48 32 1
265 VIJAYA 37 3 2 1 0 80 56 48 32 1
            
 * Age Group  ** Sex  ***NYHA       
 1- 10-19 years  1- Female  1- Class I       
 2- 20-29 years  2-Male  2-Class II       
 3-30-39 years    3-Class III       
 4- 40-49 years           
 5-> 50 years           
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